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Multiple mechanisms have been implicated in the genesis of early afterdepolarizations 
(EADs) leading to torsade de pointes (TdP) under long QT syndrome (LQTS). In atrial 
fibrillation (AF), recent studies have provided new insights into the molecular determinants of 
atrial structural remodeling pointing out to the importance of fibrosis, as both a cause and a 
therapeutic target. Physiological experiments combined with mathematical modeling have direct 
implications to the understanding the effect of drugs and to the treatment of cardiac arrhythmias.  
Ranolazine (Ran) approved by the FDA in 2006 as an anti-anginal and anti-ischemic 
drug, is known to inhibit multiple ionic currents. Functionally, Ran has been shown to suppress 
EADs in drug-induced long QT type 2 (LQT2), however, its mode of action still remains 
unknown. Our studies indicated that Ran reduces the open probability (Po) of ryanodine 
receptors (RyR2), inhibits the SR Ca
2+
 overload and combined with its effect on late sodium 
current (INa,Late) suppressed EADs. Reactivation of the L-type Ca
2+
 channel (ICa,L) has also been 
shown to play a major role in EAD formation under LQTS. In several pathological conditions, 
ICa,L has a larger window current promoting Ca
2+
 overload and EADs. Dauricine (Dau), a 
Chinese herb has been shown to impart antiarrhythmic properties. Our experimental studies 
confirmed that Dau suppressed EADs primarily by reducing ICa,L by slowing down its kinetics. 
Further investigation suggested that a minor shift in voltage-dependent activation and/or 
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inactivation parameters can suppress EADs and can be utilized as a novel antiarrhythmic 
strategy.  
Atrial Fibrillation (AF) is associated with substantial cardiovascular morbidity and 
mortality. In this study, we tested the hypothesis that atrial fibrosis plays a key role in AF 
inducibility in spontaneously hypertensive rats (SHR) and evaluated the efficacy of relaxin 
(RLX) at reducing AF inducibility by reducing fibrosis. Wistar Kyoto (WKY), SHR, and SHR 
treated with RLX (SHR+RLX) were optically mapped, tested for AF inducibility. SHR had 
slower conduction velocity (CV), higher fibrosis and a greater AF inducibility compared to 
WKY. RLX-treatment significantly reduced fibrosis levels, improved CV, and attenuated the AF 
inducibility in SHR. These studies demonstrate the relationship between fibrosis and AF and 
provide compelling evidence that reversal of fibrosis, by drugs such as RLX may provide a novel 
therapy in the management of AF. 
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1.0  INTRODUCTION 
The long QT 2 (LQT2 type) is the second most common type of congenital long QT 
syndrome (LQT), comprising about 25 to 30 percent of all cases. This form of LQT involves 
mutations of the human ether-a-go-go related gene (hERG) also known as KCNH2 on the long 
arm of chromosome 7. The hERG gene product, Kv11.1 is the pore-forming subunit of the IKr 
potassium channel (the rapid component of the delayed rectifier current). The IKr current is 
mainly responsible for the termination of the cardiac action potential, and therefore the length of 
the QT interval. Many substances used in clinical medicine inhibit IKr causing drug-induced 
LQT2.
1, 2
 
Factors that prolong the duration of the action potential (AP), mainly by delaying the 
repolarization phase 3, and increasing duration of the plateau phase 2 would lead to QT 
prolongation. Thus, potential proarrhythmic indicators at the protein level would include changes 
in ion channel properties consistent with increases in AP phases 1, 2 and/or 3. Phase 1 is the 
notch caused by transient outward potassium current (Ito). The plateau phase, phase 2, is 
maintained by inward Ca
2+
 current flowing through L-type Ca
2+
 channels (ICa,L)  that inactivate 
slowly and outward K
+
 flowing potassium channels primarily via the inward rectifier current 
(IK1) and followed by the delayed potassium currents IKr and IKs. Thus, proarrhythmic conditions 
associated with phase 2 sustained depolarization include increases in maximum conductances of 
ICa,L and INa, and changes in gating parameters consistent with slowing of inactivation and/or 
 2 
increases in the reversibility of inactivation. Repolarization (phase 3) is accomplished through 
the activity of two types of outward potassium currents, IKr, and IKs.
3
 Prolongation of the action 
potential can result from decreased inactivation of the inward Na
+
 or Ca
2+
 currents, increased 
activation of the Ca
2+
 current, or inhibition of one or more of the outward K
+
 currents. The rapid 
and slow components of the delayed rectifying potassium current, IKr and IKs, play a crucial role 
in determining the duration of the action potential and thus the QT interval.  
Figure 1: Ventricular action potential 
A schematic of the activity of the currents during an action potential 
Reproduced with permission from Kinter et al 
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While there is a general consensus in the literature that EADs are the events that initiate Torsade 
de Pointes (TdP), controversy still exists regarding the initiation of EADs. Experiments have 
suggested that EADs occurs primarily at the conduction system. However, dual optical mapping 
of APs and intracellular Ca
2+
 (Cai) showed that Cai rises before the rise of EADs and that the 
occurrence of EADs was the same in intact hearts and hearts with cryoablated Purkinje fibers.
4
 
Recently our lab has shown that in LQT2, Cai oscillations (CaiO) precede EADs by minutes, 
indicating that they result from spontaneous sarcoplasmic reticulum Ca
2+
 release rather than 
spontaneous ICa,L reactivation. CaiO leads to oscillations in INCX. Depolarizing INCX during the AP 
plateau contributes to the generation of EADs by re-activating Ca
2+
 channels that have recovered 
from inactivation.
5
 The arrhythmia phenotype is the result of complex interplay between a loss of 
function of IKr and an up-regulation of ICa,L and INCX.  
1.1 PREDICTORS OF DRUG-INDUCED TDP 
The concept of ‘repolarization reserve’ was introduced to explain congenital variability 
and sex-differences in the response to reduced or loss of function of IKr.
6
 Reduced IKr may not 
lead to clinical consequences, if, as proposed, IKs remains intact and functions as a major source 
of ‘repolarization reserve’ that protects against Torsade de Pointes (TdP) during IKr block.
7
 
However, it should be emphasized that IKs is typically a very weak current until activated by β-
adrenergic agonist and is heterogeneously distributed, being high at the base and low at the apex 
of the ventricles.
8, 9
 Multiple mechanisms are increasingly recognized as contributing to normal 
repolarization. It is clear that none of the ‘gold standard’ QT-related assays (hERG, APD and in 
vivo QT assays) alone can sufficiently predict the risk of TdP nor is there consensus on the 
 4 
parameters that best predict proarrhythmia, highlighting the complexity of the issue and the need 
for proarrhythmic models that encompass most if not all of the predisposing factors. The 
emergence of proarrhythmic models and in particular in vitro and in silico models is a testament 
to the prevalence of the problem and the urgency with which it is being tackled.
7
 
In addition to the prolongation of APDs, it is now recognized that transmural and apex-base 
dispersion of repolarization (DOR) and other properties, such as EADs, reverse frequency 
dependence, and triangulation of the AP, are associated with TdP.
8, 10
 Although there may be 
disagreement on which is the most predictive proarrhythmic model or which variable(s) are of 
greater importance, there is a general consensus that a key event linked to the induction of TdP is 
the development of EADs. EADs have been identified in every model as being the primary 
trigger of TdP.
11
 Of equal importance is to identify the components critical to the development of 
EADs and to target them as an antiarrhythmic therapy to prevent TdP. 
1.2 DRUG INDUCED QT PROLONGATION AND TDP 
The congenital and drug induced forms of LQT2 are associated with an increased risk of 
polymorphic ventricular tachyarrhythmia (PVT), called TdP. Pharmacological agents were 
developed to inhibit IKr, prolong QT interval to presumably increase refractoriness and to act as 
antiarrhythmic. These agents called class III antiarrhythmics where found to be highly 
proarrhythmic in clinical tests due to LQT-related EADs that progressed to TdP. Quinidine, 
Dofetilide and E4031 are examples of such drugs. Besides class III agents, many non-cardiac 
drugs have also been reported to cause QT prolongation and/or TdP by blocking IKr. It has since 
become apparent that hERG is a promiscuous peptide that readily interacts with a wide range of 
 5 
compounds to prolong APD. The danger of drug induced pro-arrhythmia is therefore widespread 
and remains a serious problem. However, an increase in the QT interval does not necessarily lead 
to TdP, and the correlation between the degree of QT prolongation and the risk of TdP is 
relatively weak.
12
 This issue has been identified as a considerable public health problem and has 
attracted attention from the drug regulatory authorities. Several in vitro strategies are currently 
being used to assess the proarrhythmic risk of new compounds. These include (i) the arterially 
perfused left ventricular wedge preparation, (ii) SCREENIT, a Langendorff-perfused isolated 
rabbit heart preparation and (iii) a Langendorff-perfused isolated rabbit heart preparation using 
bradycardia and hypokalemia. The rabbit heart has been routinely used in langendorff 
preparations, primarily because of its sensitivity to TdP-like arrhythmias and its similarities to 
human hearts. This sensitivity results from the rabbit heart having long APD, very low 
expression of IKs (slow component of the delayed rectifier potassium current) at the abse of the 
heart and a repolarization reserve similar to man.
7
 The ICHS7B guideline recommends a non-
clinical evaluation of the potential for delayed ventricular repolarization to 1) identify the 
potential of a test substance and its metabolites to delay ventricular repolarization, and 2) relate 
the extent of delayed ventricular repolarization to the concentrations of a test substance and its 
metabolites. The study results can be used to elucidate the mechanism of action and, when 
considered with other information, estimate risk for delayed ventricular repolarization and QT 
interval prolongation in humans (QT Interval Prolongation) by pharmaceutical therapeutics.
13
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1.3 OPTICAL MAPPING 
Optical mapping is an especially powerful tool in studies of electrophysiology. Due to 
overwhelming stimulus-induced artifacts, the conventional electrode techniques are not able to 
record electrical activity during and immediately after a stimulus. In contrast, optical recordings 
provide an accurate account of transmembrane potential changes and calcium transients (CaiT) in 
the heart.  
Fluorescence imaging at high spatial resolution but low dynamic range and low temporal 
resolution was first used to visualize ocular dominance and orientation selectivity from the 
primate visual cortex using a video camera. Development of CMOS cameras offer considerable 
advantages compared to CCDs, photodiode arrays and video cameras by achieving outstanding 
acquisition rates (up to 10,000 fps), high dynamic range (10
5
), high spatial resolution (100x100 
pixels), low background noise, and large pixel dimensions. 
Application of CMOS cameras of high spatio-temporal resolution compared to CCDs, 
photodiode arrays assures the accuracy of the recordings. Depending on optical magnification, 
the fluorescent signal comes from hundreds or thousands of cells or from multiple sites on a 
single myocyte. Also, based on the scan length, multiple action potentials can be recorded as a 
function of time from each pixel. 
1.4 CARDIAC ELECTROPHYSIOLOGY MODELS 
Mathematical modeling of cardiac cellular electrophysiology has undergone significant 
development over the last few years driven by major technological developments that have 
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provided improved experimental techniques and ever-increasing computational power. Improved 
experimental techniques have allowed scientists to examine cellular structure and function from 
the whole cell down to individual molecules and atoms while increased computational power has 
provided modelers with a critical tool required for the analysis of an immense amount of 
experimental data available. Over the last 50 years, the use of computer modeling to better 
understand the heart and its functions has reached a high level of complexity. Furthermore, 
experimental cardiac electrophysiology has been increasingly complemented by computational 
models of action potential propagation that embed models of membrane excitability within a 
framework that describes cardiac tissue and can provide a quantitative description of action 
potential propagation, and have explanatory power because they can be used to test and generate 
hypotheses that are difﬁcult to address experimentally.14 These models are becoming 
increasingly useful tools with an important part to play in understanding human physiology, 
whilst reducing and replacing animal use in cardiac electrophysiology, and possibly in the study 
of other diseases and organ systems in the future. While it appears straightforward to build 
models of cardiac tissue electrophysiology, these models embed several important assumptions 
which limit their applicability in clinical situations.
15
 Computational models for profiling 
proarrhythmic risk have made significant advances in recent years. Highly sophisticated  in silico 
models have been developed to predict hERG channel activity
16
, AP duration in rabbit
17-19
, 
canine
20
, and human ventricular myocytes
21, 22
 and electrical wave propagation throughout the 
intact myocardium.
23, 24
 These models may be useful to examine the mechanism of a particular 
aspect of cardiac function. However, biological systems are vastly more complex than any 
modeled system and so it is extremely unlikely that we will be able to reproduce the complex 
properties found in nature with high fidelity with just a few decades of investigations. 
 8 
1.5 MODELS OF APs AND CaiT 
Models of APs and CaiT are based on ionic currents, ionic concentrations, subcellular 
organelles, membrane processes and other processes which regulate intercellular Ca
2+ 
concentration. All models depict ionic fluxes of each species as independent of the others. When 
a current I is included as one of the reactions in a model, that current will appear on the right 
hand side (RHS) of 2 ordinary differential equations (ODEs): dV/dt (voltage) and d[c]/dt (where 
[c] is an ionic concentration). Equation 1 is a representative of the monovalent time- independent 
Nernst current and applies to all the ionic currents; hence a similar equation is used for Na
+
, K
+
, 
Ca
2+
 and Cl
-
. For this current,  
 
 
where 
Equation 1 
 
  
 
Equation 2 
 
G, n, [c]o, V1/2, are parameters. [c] and V (voltage) are state variables. T, R, and F are constants. 
 Several models of ion channel dynamics are used in the literature.  The original Hodgkin-
Huxley formulation 
25
 assumed that the transition from a closed state [C] to an open state [O] 
(and vice versa) were determined by a voltage dependent rate constant (V) and ( (V) for the 
reverse reaction) that depended exponentially on V. The differential equation that results from 
this model (assuming only 1 open and 1 closed state) is,  
 
 
 
Equation 3 
 
can then be reorganized in terms of new quantities [O]inf and , such that  
 9 
 
 
 
Equation 4 
 
  
 
Equation 5 
 
However, investigators have generalized this model such that the quantities [O]inf and  no 
longer are forced to take on the form given above. 
26, 27
  Therefore, we will define any transition 
between any states of an ion channel in which the rate constants are exponential functions of V 
to be of “Markov type”. An example of a Markov formulation is given below:  
 
OC  
 
Equation 6 
 
 
 
 
Equation 7 
 
 
 
 
Equation 8 
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2.0  RANOLAZINE STABILIZES CARDIAC RYANODINE RECEPTORS: A NOVEL 
MECHANISM FOR THE SUPPRESSION OF EADS AND TDP IN LONG QT TYPE 2 
2.1 SPECIFIC AIMS 
Ranolazine (Ran) is known to inhibit multiple targets, including: the late Na
+
 current, 
INa,Late, the rapid delayed rectifying K
+ 
current, IKr, L-type Ca
2+
 current, ICa,L, and fatty-acid 
metabolism. Functionally, Ran suppresses EADs during phase 2 and/or phase 3 and TdP in drug-
induced LQT2, presumably by decreasing intracellular [Na
+
]i and Ca
2+ 
overload.  
The goal of the proposed research was to compare the available in silico models of rabbit 
ventricular myocytes to experimental data and to elucidate the mechanism(s) whereby Ran alters 
APs, CaiT and suppresses EADs and (TdP) in LQT2 using optical mapping and mathematical 
modeling. 
Aim 1: To test the hypothesis that in LQT2 (or IKr inhibition) elevation of ICa,L 
promotes EADs based on the best available in silico models of ventricular APs and Cai 
handling. 
 Several in silico models for the rabbit cardiac ventricular myocytes were tested and the 
best available model based was selected based on its ability to predict correct AP and Ca
2+
 
dynamics. The AP and CaiT were quantitatively and qualitatively compared with experimental 
data recorded at 3 different heart rates. The model/models that best predicted the correct Ca
2+
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dynamics were used for further studies. The models were also tested for their ability to generate 
EADs based on the inhibition of IKr and elevation of ICa,L. 
Aim 2: To test the hypothesis that Ran suppresses arrhythmias in a drug-induced 
LQT2 using optical mapping and elucidate its mode of action using bilayer studies and 
mathematical modeling. 
 A therapeutic concentration of Ran was tested in rabbit hearts to study its effect 
on a) APD, CaiT, Cai rise time and Vm-Cai delay, b) antiarrhythmic properties in the suppression 
of arrhythmias in a model of drug-induced LQT2 and c) it’s effect on the open probability of 
ryanodine receptors (RyR2). The action of Ran on various ionic currents and RyR2 was 
modelled in a step wise manner in the best available in silico model as determined from Aim 1 
and was used to explain its primary mode of action. 
2.2 INTRODUCTION 
Ran (2-6 µM) is approved for the treatment of angina pectoris and ischemic heart 
disease, but its exact therapeutic mode of action remains controversial. Early studies suggested 
that Ran altered myocardial energy metabolism by reducing fatty acid oxidation and glucose 
oxidation.
37
 The inhibition of fatty oxidation by Ran appeared at relatively high concentrations 
(12% inhibition at 100 µM) which brought into question the validity of this mode of action.
37-39
 
Alternatively, Ran at therapeutic doses (<10 µM) was shown to inhibit INa,Late.
40
 Besides its 
efficacy in the treatment of angina pectoris, Ran suppressed EADs and TdP in animal models of 
acquired LQT2
41
 despite its tendency to prolong the QT interval by inhibiting IKr.
42
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Ryanodine receptor (RyR2) plays a major role in cytosolic Ca
2+
 release and is critical in 
arrhythmogenesis of different pathologies and as a target of antiarrhythmic drugs. Ca
2+
 released 
from the sarcoplasmic reticulum (SR) occurs in a wavelike form with a swing of levels from 100 
nM to 1 µM. For ventricular contraction,  Ca
2+
 release occurs via the entry of extra cellular Ca
2+
 
via ICa,L in small sparks
28
 that unleash a  large release from SR via RyR2 
29
 and the withdrawal 
via SERCA pump
30, 31
. The amplitude of the transient is governed several factors – SR calcium 
load
32
, luminal Ca
2+
 
33, 34
, and is proportional to the contractility 
31, 35, 36
. The inhibition of the 
INa,Late window results in a decrease of intracellular Na
+
 and improved extrusion of Ca
2+
 via 
INCX.
43-45
 Inhibition of INa,Late could account for the therapeutic effects of Ran because it would 
lead to a reduced Cai load, which would reduce bioenergetic stress, protect the heart from 
ischemic injury, and suppress the incidence of EADs. But, contrary to expectations, ranolazine 
had no significant effect on peak Cai. This observation lead us to the hypothesis that ranolazine 
lowered the SR Ca
2+
 leak, primarily by reducing the open probability of RyR2. 
 Modeling the actions of Ran based on its IC50 values at its known targets failed to predict 
Ran’s suppression of EADs in LQT2. We hypothesize that antiarrhythmic effect of Ran in the 
setting of LQT2 cannot be understood without including additional sites of action that alter 
intracellular Ca
2+
 handling, which to date have not been identified.  
 13 
2.3 MATERIALS AND METHODS 
2.3.1 Heart preparations and optical mapping 
New Zealand White rabbits, (adult females >60 days old, ~2kg) were injected with pentobarbital 
(35 mg kg
-1
, I.V.) and heparin (200 U kg
-1
) via an ear vein; the heart was excised and 
retrogradely perfused through the aorta with Tyrode’s solution (in mM): 130 NaCl, 24 NaHCO3, 
1.0 MgCl2, 4.0 KCl, 1.2 NaH2PO4, 50 dextrose, 1.25 CaCl2, at pH 7.4, gassed with 95% O2 and 5 
% CO2. Temperature was maintained at 37.0 ± 2 °C and perfusion pressure was adjusted to ~70 
mmHg with a peristaltic pump.
46
 The atrio-ventricular node was ablated by cauterization to 
control rate (500-2000 ms). The heart was stained with a bolus of a voltage-sensitive dye (RH 
237 or PGHI; 50 µl of 1 mgml
-1
 in dimethyl sulfoxide, DMSO) and a Ca
2+
 indicator (Rhod-
2/AM, 300 µl of 1 mgml
-1
 in DMSO) delivered through the bubble trap, above the aortic 
cannula. The hearts were oriented to view the anterior surface, record control APs and CaiT then 
add E4031 (0.5 μM) and/or Ran to the perfusate. E4031 was purchased from Sigma-Aldrich (St 
Louis, MO) and Ran was the kind gift of Dr. Luiz Belardinelli (Gilead Sciences, Palo Alto, CA). 
The optical apparatus based on 2 (16x16 pixels) photodiode arrays has been previously 
described.
46, 47
 Each pixel viewed a 0.9x0.9 mm
2
 area of myocardium and images were acquired 
at 1,000 frames/s. 
2.3.2 Single channel recordings of cardiac ryanodine receptors (RyR2) 
Cardiac SR vesicles (5-10 µg/ml) isolated from sheep ventricles 
48
 were added to the cis-
chamber of a planar bilayer setup containing 400 mM Cs
+
CH3O3S
-
, 25 mM Hepes, pH 7.4, while 
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the trans-side contained 40 mM Cs
+
CH3O3S
-
, 25 mM Hepes, pH 7.4. Bilayers were made of 
5:3:2 phosphatidylethanolamine (PE): phosphatidylserine (PS): phosphatidylcholine (PC) 
(Avanti Polar Lipids – Coagulation reagent 1) painted across a 150 µm hole separating two 
compartments. Following fusion of an SR vesicle to the bilayer, 4M Cs
+
CH3O3S
-
, 25mM Hepes, 
pH 7.4
 
was added to the trans-side to equalize the salt concentration at 400 mM. Channel output 
was filtered at 0.8-1.0 kHz and traces were recorded at a holding potential of -40 mV, for not less 
than three minutes following an addition of Ran to the cis-chamber. Single channel analysis was 
carried out using the ClampFit program (Axon Instruments: pClamp software). The Po (mean ± 
SE) normalized to 1 (control without Ran) was plotted as a function of [Ran] (n = 7).
49
  
2.3.3 Ca2+ dependent ryanodine binding to RyR2 
Equilibrium ryanodine-binding was measured as a function of free Ca
2+
 (Caf) in buffer 
containing 250 mM KCl, 15 mM NaCl, 2 nM [
3
H]ryanodine, 13 nM unlabeled ryanodine, 20 
mM PIPES, pH 7.1 ± 30 µM Ran at an SR concentration of 0.5 mg/ml, following 3 hours 
incubation at 37
o
C.
50
 Nonspecific binding, measured in the presence of 200 nM unlabeled 
ryanodine and 50 µM Ca
2+
+ 4 mM EGTA, was subtracted from all measurements. Ca
2+
 was 
buffered with EGTA and Caf was calculated with established binding constants and measured 
with a Ca
2+
-selective electrode. 
2.3.4 Mathematical modeling 
The mathematical representation of a typical ionic current is based upon the Hodgkin 
Huxley representation,  
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Current = Conductance * Driving Force 
For instance, the kinetics of the rapid delayed rectifier current IKr is shown below,    
 
IKr = GKr * X * R *(V – EKr) 
 
Equation 9 
 
GKr = Conductance of the channel, X = activation gate of IKr, R = inactivation gate of IKr, 
V= Membrane potential, EKr= Reversal potential of potassium. 
In order to mimic low expression levels of the IKr (the blockade of the IKr channel), we 
multiply the conductance by a numerical value < 1. For 50% blockade of IKr, GKr is multiplied by 
a numerical value of 0.50; for 40% blockade 0.6. Similarly, to increase the expression levels of 
ICa,L, the conductance of L-type calcium channel is multiplied by a numerical value > 1. For 10% 
increase in ICa,L, we multiply the conductance by 1.10; for 30% increase, we multiply by 1.30.  
APs and CaiT predicted by the Shannon
17
 and Mahajan
51
 models were compared to optical 
recordings at various CLs (500, 1000, 2000 ms). Simulations of LQT2 included: a) a 50 % 
decrease of IKr, to mimic the effect of E4031, b) a 32% increase of ICa,L to mimic the increase in 
ICa,L expression measured in females hearts and shown to be a key factor for the higher risk of 
TdP in female hearts,
52
 c) an increase in cycle length to 1 or 2s since bradycardia is a critical co-
factor to promote EADs.  The multifaceted action of Ran was modeled by modifying the channel 
conductance using the following values: IKr (IC50 = 12 µM), INa,Late (IC50 = 5.9 µM), ICa,L (IC50 = 
50 µM), and INCX (IC50 = 91 µM).
42
 To incorporate a dose dependent effect the conductance of 
the major ionic currents (IKr, INa,Late, ICa,L and INCX) was scaled using the equation,  
   
 
 
Equation 10 
 
 
 16 
where Gi, Ran: Conductance of ionic current ‘i’ with Ranolazine, Gi: Original conductance for 
current ‘i’, i = IKr or INa,Late or ICa,L or INCX. 
The code for Shannon model was provided by Dr. Jose Luis Puglisi (UC Davis, CA) and 
was compiled in Matlab, while the code for the Mahajan model was provided by Dr. Alain 
Karma (Northeastern University, Boston, MA) and was compiled in C++.  
2.3.5 Analysis 
APDs, CaiT, rise-times, durations, amplitudes and Vm to Cai delays were measured at regular 
intervals. Measurements of duration are expressed as mean  SEM; Student’s t –Test (paired) 
was applied to determine statistical significance based on p <0.05. 
2.4 RESULTS 
2.4.1 Effects of ranolazine on APs and CaiTs after IKr block 
Figure 2 illustrates representative traces of optical APs and CaiT from the base of the left 
ventricle. Control recordings showed that CaiT followed the AP upstroke by 10 ms and 
recovered after the local repolarization (panel A). E4031 (0.5 µM) added to the perfusate 
prolonged APD, induced CaiT oscillations and elicited EADs (panel B, n = 7/7). The latter 
increased in frequency degenerating into salvos of EADs (<10 min). However, perfusion with 
Ran (10 µM) plus E4031 suppressed EADs within 5 min (panel C) and abolished the progressive 
worsening of the electrical instabilities to TdP. In panels A’ to D’, the order of addition of the 
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two drugs was reversed; Ran (10 µM) added alone prolonged APDs (204  6.1 ms to 240  7.8 
ms; p <0.05), CaiT (249  23.5 ms to 275  43.1 ms) and Cai rise-time (26  1.2 ms to 42  3.0 
ms; p <0.05) (compare A’ to B’). The subsequent addition of E4031 (0.5 µM) failed to prolong 
APDs and to elicit EADs (panel C’). Ran was then washed out while keeping E4031 resulting in 
a marked APD prolongation, giving rise to EADs and TdP (panel D’). The washout of Ran 
exposed the proarrhythmic effect of E4031 and the protective effects of Ran. Table 2 
summarizes the statistically significant effects of Ran and E4031 on APDs and CaiT. 
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Table 1: Summary of Parameters - Effect of E4031 and ranolazine 
 
APD 
(ms) 
CaiT Duration 
(ms) 
Vm-Cai delay 
(ms) 
CaiTRise-Time 
(ms) 
Control (n = 8) 204  6.1 249  23.5 6.3  0.7 26  1.2 
E4031 only (n = 7) 546  34.9* 582  21.9* 5.8  0.7 43  2.7* 
Ranolazine only (n = 6) 240  7.8 * 275  43.1 5.8  0.8 42  3.0* 
E4031+Ranolazine (n = 7) 306  27.1*! 343  51.0*! 6.0  1.3 43  4.6* 
* versus Control p < 0.05; ‡versus E4031 only p < 0.05 
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Figure 2: Ranolazine suppresses EADs and TdP in LQT2 
Left Panel: Vm (blue) and Cai (red) measured from the same site at the base of the heart. 
A: Control AP and CaiT with the heart was paced at 2 s CL 
B: 10 min after E4031 (0.5 µm)  
C: 10 min after E4013 plus Ran (10 µM)  
Right Panel: The two drugs were added in the reverse order. 
A': Control, 15 min after Ran  
B': 10 min after Ran plus E4031  
C': 5 min after washout of Ran but with E4031  
D': Washout of Ran prolonged APD and unmasked EADs due to the presence of E4031 
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2.4.2 Modeling I- Selection of the model and modeling the action of ranolazine 
Highly sophisticated in silico models have been developed to predict the shape and time-course 
of APs and CaiT in ventricular myocytes for different species 
53
, with the Shannon 
17
 and the 
Mahajan
51
 models being specifically designed to incorporate experimentally determined 
properties of rabbit ventricular myocytes. The Shannon model contains a robust representation of 
excitation-contraction coupling, in which the properties of SR Ca
2+
 release include 
inactivation/adaptation and a non-linear dependence on SR Ca
2+
-load. Apart from the addition of 
a subsarcolemmal compartment to the other two commonly formulated cytosolic compartments 
(junctional and bulk) because ion channels in the membrane sense ion concentrations that differ 
from bulk; it also included, a reversible sarcoplasmic reticulum (SR) Ca pump and a scheme for 
Na-Ca exchange transport that is [Na]i dependent and allosterically regulated by [Ca]i.  
On the other hand, the Mahajan model includes a minimal seven-state Markovian model 
of ICa,L, which incorporates voltage-dependent inactivation (VDI) and Ca
2+
-dependent 
inactivation (CDI) and an Cai cycling component, to incorporate a phenomenological model 
emulating local control that produces the appropriate instability leading to CaiT alternans at rapid 
heart rates. Both the models include advanced calcium cycling kinetics, critical for the 
development of EADs.  
Figure 3A compares the APs and CaiT obtained with the Shannon (a) or Mahajan (b) 
model and the experimental data (c) at three different CLs (500, 1,000 and 2,000 ms). In Figure 
3B, APD90, CaiTD75, Cai rise-time and Peak-CaiT amplitude were calculated and compared at the 
three CLs for the experimental data (blue bars), the Shannon (red bars) and the Mahajan (green 
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bars) models. Based on quantitative comparisons, APD90 for the two models predicted closely the 
optical recordings at 500 ms CL, but at 1,000 ms CL, the Shannon was close but the Mahajan 
model deviated significantly predicting longer APD90 than optical APD90 and at 2,000 ms CL, the 
Shannon model underestimated and the Mahajan model overestimated the experimental APD90 
(Figure 3Ba). The duration of CaiT measured at 75% recovery to baseline, CaiTD75 were similar 
for the Shannon and experimental values but the Mahajan model deviated significantly, at all 
three CLs. Similarly, the Shannon and experimental values were considerably closer to each 
other than the values predicted by the Mahajan model for the rise time and peak of CaiT. For 
peak-CaiT the signals were normalized at 500 ms CL and changes in peak-CaiT were compared 
for the longer CLs. The Mahajan model predicted markedly slower rise-times and smaller peak-
amplitudes of CaiT and rather abnormal shape and time courses of CaiT, particularly at longer 
CLs. 
When the models were tested for their ability to mimic experimental LQT2 conditions, 
the Shannon model generated EADs. However, the Mahajan model failed to generate EADs 
(Figure 3C). Upon further inhibition of IKr, and elevation of ICa,L, there was an increase in the 
APD but no EADs appeared (Figure 3C).  Based on the closer fit to experimental data and ability 
to generate EADs, we chose the Shannon model to simulate the actions of Ran. 
The effect of Ran was simulated based on its IC50 values on the major ionic currents.
54
 However, 
the model failed to predict the suppression of EADs by Ran (Figure 4), suggesting that our 
understanding of the actions of Ran was incomplete within the context of prescribed model 
parameter changes. 
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Figure 3: Comparison of mathematical models with experimental data 
A: APs (top) and CaiT (bottom) derived from Shannon (a) and Mahajan (b) models and 
optical signals from rabbit hearts (c) at different CLs (500 (black), 1,000 (blue) and 2,000 
ms (red)). B: Quantitative comparison of APD90 (a), CaiT75 (b), CaiT rise-time (c) and 
peak-CaiT (d) between mathematical models (Shannon, red; Mahajan, green) and 
experimental data (blue). C: Predicted APs at 2 s CL by the Shannon model (a); control in 
blue and LQT2 in red and by the Mahajan model (b); control in blue and LQT2 in red.  
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Figure 4: Modeling I - Antiarrhythmic effect of ranolazine 
Steady state APs and CaiTs for the last four beats in a train of 75 pulses at 2 s CL under LQT2 
condition (black); under LQT2 plus 10 µM Ran (blue). Ran failed to suppress EADs. 
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2.4.3 Effects of ranolazine on RyR2 
Cardiac SR vesicles isolated from sheep ventricles were fused to planar bilayers and 
single channel open-probability (Po) was recorded in the presence of 50 µM Ca
2+
 on the cis-side 
at pH 7.4. Figure 4A illustrates single channel recordings as a function of [Ran] from the same 
bilayer. Figure 5B plots the normalized Po (derived from 2 min of continuous recordings) as a 
function of [Ran]. The data were fit to a four parameter logistic curve (Sigma-Plot) which 
yielded an IC50 of RyR2 inhibition equal to 10 ± 3 µM (mean ± SE, n = 7). In figure 5C, 
equilibrium high-affinity ryanodine binding is plotted vs. [Ca
2+
] in the absence and presence of 
30 µM Ran. These data was fitted to a Hill Plot. Ran shifted the EC50 for Ca
2+
 dependent 
activation of ryanodine binding from 0.42 ± 0.02 µM to 0.64 ± 0.02 µM, but has negligible effect 
on the degree of co-operativity (Hill co-efficient=2.5) or the maximum level of ryanodine 
binding. At 10 and 30 µM Ran, the Ca
2+
 dependence of [
3
H] ryanodine binding shifted to the 
right, respectively by 80 (not shown) and 220 nM Ca
2+ 
(Figure 5C). 
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Figure 5: Effects of ranolazine on Po of RyR2 and Ca
2+
-dependent [3H] ryanodine binding 
A: Characteristic single channel fluctuations following fusion of cardiac SR vesicles to a 
planar bilayer as a function of [Ran]. Po was measured in the presence of 50 µM Ca
2+
 to 
maintain a highly active channel (i.e. Po ~0.5) and was averaged over 2 min of continuous 
recordings. c = closed, o = open state. 
B: Normalized Po±SE vs. [Ran], n = 7.  
C: Ryanodine-binding vs. free [Ca
2+
] (Ca
2+
-selective electrode). Ryanodine binding was 
measured ± 30 µM Ran with SR vesicles (0.5 mg/ml), data are average ± SE (n = 4). 
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2.4.4 Modeling II 
To fully model the effects of Ran, Po of RyR2 was modified as a function of Ran 
concentration according to single channel bilayer experiments, in addition to its other targets. 
The model correctly predicted experimental findings of Ran under normal and LQT2 condition. 
In controls (Figure 6), Ran at 5 µM prolonged APD by 8ms and decreased peak-CaiT by 
17%. While at 10 µM, Ran prolonged APD by 15 ms, increased CaiT rise-time by 1.9 fold and 
decreased peak-CaiT by 35%, as previously reported.
54
 The simulation also predicted that Ran 
reduces the AP ‘notch’ most likely due to its effect of the late Na+ current, but does not alter the 
voltage during the AP plateau phase. The effect of Ran on the notch is not detected by optical AP 
measurements because optical recordings smooth out the notch since they represent the sum of 
thousands of APs from myocytes under the field-of-view. In LQT2 (Figure 7), Ran (5 µM) 
decreased Cai overload but was not effective at suppressing EADs. At 10 µM, Ran suppressed 
EADs and reduced Cai overload, highlighting a concentration-dependent suppression of EADs.  
Figure 8 investigates the mechanisms of action of Ran in LQT2 by testing its known effects, 
except for the inhibition of RyR2, and then including RyR2 inhibition. The stimulation 
demonstrates that RyR2 inhibition by Ran is required to suppress EADs. 
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Figure 6: Modeling the effect of ranolazine on APs and CaiTs 
Top traces: Steady state APs and CaiTs at 500 ms CL from the Shannon model at control 
(blue), 5 µM (black) and 10 µM (red) Ran. Bottom traces: APs and CaiTs shown at faster 
sweep speed. 
 28 
 
Figure 7: Modeling II - Various [Ran] in LQT2 model 
APs and CaiTs from the Shannon model showing the last four beats from a train of 75 pulses 
at 2 s CL (black), with LQT2 (red), LQT2 plus 5 µM Ran (blue) and LQT2 with 10 µM Ran 
(green). EADs persisted with 5 µM but not 10 µM Ran. 
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Figure 8: Modeling the antiarrhythmic effect of ranolazine when RyR2 is inhibited 
APs and CaiTs (Shannon model) showing the last four beats after 75 pulses at 2 s CL with 
LQT2 (black); with LQT2 and 10 µM Ran but without (blue) and with RyR2 inhibition (red).  
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2.5 DISCUSSION 
The effects of Ran on the normal AP and its suppression of EADs in LQT2 hearts were 
identified using optical mapping. The main finding was that the Shannon model reproduced the 
experimentally measured AP and CaiT at various CLs and the initiation of EADs. However, the 
model failed to predict the suppression of EADs and TdP after inserting the currently known 
effects of Ran which contradicted experimental observations. Our experimental data further 
shows that Ran reduced Po of RyR2 reconstituted in planar bilayers and desensitized RyR2 to 
Ca
2+
-dependent activation. Mathematical simulations that included these changes in the Po of 
RyR2 caused by Ran, predicted the suppression of EADs indicating that the antiarrhythmic 
effects of Ran are dependent on its effect on RyR2. More precisely, the model required a 
reduction of Po by 50% (as would be expected by ~10 µM Ran) along with the inhibition of 
INa,Late to protect the heart from SR Ca
2+
 overload and to suppress EADs. At 10 μM, Ran acts at 
multiple targets;
54
 by inhibiting IKr, Ran prolongs APDs and QT intervals, yet paradoxically does 
not induce but suppresses TdP in experimental LQT1-3 models
45
. Although Ran alone prolonged 
APDs, when added after E4031, Ran reduced APDs (Figure 2C). Moreover, when hearts were 
treated with Ran followed by E4031, Ran was considerably more effective at reducing APDs 
(Figure 2C’). Although the final concentration of the two drugs is the same, the order of their 
addition produced different results. Electrophysiological studies of hERG channels expressed in 
HEK-293 cells indicated that Ran and E4031 shared the same binding domain to inhibit IKr but 
that Ran could not competitively displace E4031.
55
 Hence, there are two reasons why the two 
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conditions differ. a) When E4031 is added first, Ran cannot displace E4031 but E4031 can 
displace Ran from hERG. b) E4031 causes Cai overload, oscillation, high plateau Cai and 
spontaneous SR Ca
2+
 release which activates INCX that prolongs APDs, Ran can the reduce 
spontaneous SR Ca
2+
 release by stabilizing RyR2 but does not lower plateau Cai (Figure 2C) but 
when added first Ran inhibits the subsequent E4031-induced Ca
2+
 overload (Figure 2C’) thereby 
reducing APD more effectively. In clinical studies, Ran lowered the incidence of arrhythmias in 
survivors of acute coronary syndrome 
56
 and studies in patients with atrial ﬁbrillation are 
promising.
57
 Ran has been found to alter Ca
2+
 handling by increasing the latency of Ca
2+
 waves 
and reducing the severity of SR Ca
2+
 overload in LQT3 induced by ATX-II
58
; an effect that 
would result in reduced likelihood of Ca
2+
 overload-induced triggered activity.  
Mathematical simulation can provide a powerful tool to investigate the mechanisms of 
drug action, but first it was necessary to select and validate the model based on experimental 
observation. The Shannon model produced APs and CaiT, which were close, but not identical, to 
the optical data; an important difference being the lack of APD prolongation with longer cycle 
lengths (Figure 3A) which persisted with predictions of APD prolongation caused by Ran. The 
Mahajan model produced unrealistic CaiT at slower rates exhibiting a long rise-time to a first 
peak followed by a gradual rise of Cai before recovering to baseline (Figure 3Ab). Also, the 
peak-CaiT collapsed compared at faster rates (Figure 3Bd). In order for the Mahajan model to 
replicate LQT2 conditions, there is a need to formulate a physiologically plausible mechanism 
for spontaneous SR Ca
2+
 release in Cai-overloaded conditions, which plays a major role in the 
pathogenesis of delayed afterdepolarizations and triggered activity. Insertion of the effects of 
Ran in the Shannon model of LQT2 failed to predict Ran’s antiarrhythmic effect (Figure 4).  
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There are precedents of drug with established ‘modes-of-action’ being re-discovered for 
new properties and/or sites-of-action. For instance, flecainide, a Class IC antiarrhythmic known 
for its inhibition of INa,Late, was found to decrease the open-time of RyR2 channels and prevent 
spontaneous SR Ca
2+
-release in catecholaminergic polymorphic ventricular tachycardia.
59
 
Similarly, Ran reduced Po of RyR2 with an IC50 of 10 µM (Figure 5). The Shannon model 
predicts that RyR2 inhibition by Ran does not alter peak ICa,L but blunted ICa,L reactivation 
through a 27% reduction of INCX (-1.827 to -1.329 pA/pF) (Figure 9). Hence, Ran inhibition of 
RyR2 primarily reduced INCX thereby suppressing EADs (as in Figure 8). Moreover, lower [Ran] 
(5 µM) did not subdue EADs (Figure 7) in agreement with previous findings.
41
 [Ran] subdues 
arrhythmias at ≥ 10µM but not when [Ran] falls below the concentration required for RyR2 
inhibition. In support of this hypothesis, the MERLIN-TIMI 36 trial documented Ran’s 
antiarrhythmic efficacy at 10 µM but not at lower concentrations.
56
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Figure 9: Effect of RyR2 inhibition by ranolazine on AP, CaiT, ICa,L and INCX 
Steady state AP, CaiT, ICa,L and INCX from the Shannon model showing the last beat 
following a train of 75 pulses at 2 s cycle length with Control (blue); LQT2 (black) and 
LQT2 plus 10 µM Ran with RyR2 inhibition (red). 
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2.6 LIMITATIONS 
The Shannon model is based on ionic currents measured from rabbit and guinea pig (IKs) 
myocytes
60
 and the modulation of ionic currents by Ran was measured using guinea pig 
myocytes.
42, 54
 However, species-differences appear to be negligible because Ran has been 
shown to have similar antiarrhythmic properties in guinea pigs
54
, dogs
41
 and rabbits
61
.  
2.7 CONCLUSION 
In summary, our study applied computational techniques to discern discrepancies in the 
pharmaceutical actions of Ran which encouraged us to pursue alternative explanations. It 
allowed us to experimentally identify a new target and to confirm its validity. The findings show 
that in LQT2, Ran prevents excessive Ca
2+
 load by stabilizing RyR2 and desensitizing RyR2’s 
activation by Cai, resulting in the suppression of EADs and TdP.  
 35 
3.0  DAURICINE SUPPRESSES EADS IN LONG QT TYPE 2 BY SLOWING DOWN THE 
KINETICS OF L-TYPE Ca
2+
 CHANNEL 
3.1 SPECIFIC AIMS 
Dauricine, a bisbenzyl tetrahydrosioquinoline alkaloid derivative, has been shown to 
produce a variety of pharmacological actions, such as anti-inflammatory,
62
 anti-anaphylaxis, and 
antioxidant and has been widely used for the treatment of various pathologies in China for 
centuries.
63
 It has also been shown to affect various ionic currents in electrophysiological studies. 
In single isolated cells from guinea pigs, dauricine inhibited the late sodium current, INa,Late, 
64
 the 
delayed potassium rectifier current, IKr,
65
 and the L-type Ca
2+
 current, ICa,L.
65
 
Aim 1: To test the hypothesis that dauricine suppresses arrhythmias in a model of 
drug-induced LQT2 in a whole heart langendorff preparation using optical mapping 
 A therapeutic concentration of dauricine was tested in control rabbit hearts to 
study its effect on APD, CaiT and conduction velocity (CV) as a function of cycle length. 
Dauricine was also tested for its antiarrhythmic properties to suppress EADs in a drug-induced 
LQT2 in whole langendorff rabbit hearts and assess its effect of predictors of TdP such as 
dispersion of repolarization (DOR) and incidence of EADs. 
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Aim 2: To identify the mechanism by which dauricine suppresses arrhythmias in 
drug-induced LQT2 
Drug-induced LQT2 was modelled in the Shannon single cell action potential model. The 
antiarrhythmic property of dauricine was incorporated by modifying the ionic currents based on 
their IC50 values and changing the ICa,L window current to assess its effect on arrhythmias. The 
voltage-dependent ICa,L activation and inactivation was also altered in a step wise manner to 
assess its effect on arrhythmogenesis. 
3.2 INTRODUCTION 
In the past few decades, a major effort has been made to investigate and understand the 
pharmacological effects and the mechanism of actions of compounds used in traditional Chinese 
herbal medicines. Dauricine, a bisbenzyl tetrahydrosioquinoline alkaloid derivative (Figure 10) 
has been shown to produce a variety of pharmacological actions, and to exhibit anti-
Figure 10: Chemical structure of dauricine 
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inflammatory,
62
 anti-anaphylaxis, and antioxidant effects. Dauricine has been used to treat a 
wide range of ailments, including inflammation, allergy and arrhythmias.
63
 Recently, extensive 
research has been done to study the effect of dauricine as an antineoplastic agent. Dauricine has 
been shown to circumvent multidrug resistance cancers
66
 and has also been effective in 
inhibiting human breast cancer angiogenesis, in human breast cancer cell lines (MCF-7).
67
  
Dauricine has been shown to act at the L-type Ca
2+ 
current, ICa,L by altering the channel 
kinetics. ICa,L plays a fundamental role in the electrophysiology of the heart. ICa,L sits at a focal 
point regulating cardiac action potential duration, excitation-contraction coupling, Ca
2+
 
homeostasis and in the genesis of EADs leading to TdP.
68
 Previous work has shown that 
reactivation of the ICa,L during the action potential (AP) plateau plays a major role in EAD 
formation under LQT conditions.
69
 Another hypothesis of EAD formation proposes that APD 
prolongation promotes cellular Ca
2+
 overload, triggering spontaneous Ca
2+
 release from the 
sarcoplasmic reticulum (SR),
70
 enhancing the turnover rate of INCX,
52
 which may reactivate ICa,L. 
Both these mechanisms implicate ICa,L as a trigger of EADs. Most EADs initiate between −40 
mV and 0 mV, corresponding to the range of membrane potentials where the steady-state 
activation and inactivation curves of ICa,L overlap, often referred to as the ‘window current’ 
region.
71
 In this ‘window’, ICa,L channels which are not inactivated may be available for 
reactivation which generate the upstroke of the EAD.
72
 In dogs with chronic atrioventricular 
block (cAVB), ICa,L has a larger ‘window’ and this increases incidence of EADs under β-
adrenergic stimulation.
73
 In medicine, ICa,L is the important therapeutic target in the treatment of 
hypertension, angina, and cardiac arrhythmias.
74, 75
 Theoretical studies have also recently 
provided an insight into how the shape of ICa,L influences both excitation-contraction coupling 
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and repolarization of the cardiac AP, and proposed modification of ICa,L especially its kinetics as 
a novel antiarrhythmic strategy.
68, 72
  
3.3 MATERIALS AND METHODS 
3.3.1 Materials 
Dauricine (purity >98%) was a gift from Dr. Fan-Dian Zeng from the laboratory of Department 
of Pharmacology at the Tongji Medical College, Huazhong University of Science and 
Technology (Wuhan, China). This agent was dissolved in distilled water and HCL to make a 
stock solution (25 mM), and it was diluted to the desired final concentrations before the 
experiment. Dofetilide, a selective IKr blocker was supplied by Pfizer (NY, USA) and was 
dissolved in 100 mM sodium hydroxide (250 µg/ml) and was diluted to the final concentration 
immediately before the experiment.  
3.3.2 Isolated perfused hearts 
New Zealand White rabbits, (adult females > 60 days old, ~2 kg) were injected with 
pentobarbital (35 mg kg
-1
, I.V.) and heparin (200 U kg
-1
) via an ear vein; the heart was excised 
and retrogradely perfused through the aorta with Tyrode’s solution (in mM): 130 NaCl, 24 
NaHCO3, 1.0 MgCl2, 4.0 KCl, 1.2 NaH2PO4, 50 dextrose, 1.25 CaCl2, at pH 7.4, gassed with 
95% O2 and 5 % CO2. Temperature was maintained at 37.0 ± 2 °C and perfusion pressure was 
adjusted to ~70 mmHg with a peristaltic pump.
46
 The atrio-ventricular node was ablated by 
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cauterization to allow rate control with ventricular pacing (cycle length (CL) 300-1000 ms). The 
heart was stained with a bolus of a voltage-sensitive dye (PGH1; 50 µl of 1 mgml
-1
 in dimethyl 
sulfoxide, DMSO) and a Ca
2+
 indicator (Rhod-2/AM, 200 µl of 1 mgml
-1
 in DMSO) delivered 
through the bubble trap, above the aortic cannula. The hearts were oriented to view the anterior 
surface, record control APs and CaiT. Dofetilide (0.5 μM) and/or Dauricine (5 µM) were directly 
added to the perfusate. 
3.3.3 Optical mapping, data acquisition and analysis 
The optical apparatus based on 2 (16x16 pixels) photodiode arrays has been previously 
described.
46, 47
 The anterior surface of the heart was illuminated with a 520 ± 30 nm excitation 
beam, and the fluorescence was passed through a dichroic mirror (660 nm) to focus the Rhod-2 
and PGH 1 fluorescence images on two 16×16 photodiode arrays (C4675–103, Hamamatsu 
Corp, Hamamatsu City, Japan). Outputs from the arrays were amplified, digitized, and stored in 
computer memory. Activation and repolarization time points are taken at the maximum first 
derivative [(dF/dt)max] of the AP upstroke and the maximum second derivative [(d
2
F/dt
2
)max] of 
the AP downstroke, respectively. From the activation and repolarization time points recorded in 
one heartbeat, a computer algorithm generated isochronal maps to visualize activation and 
repolarization waves.
76
 Diodes corresponding to the edges of the heart and/or those detecting 
pronounced movement artifacts were excluded from the analysis. APDs, CaiT were measured at 
regular intervals. Local conduction velocities vectors were calculated for each diode from the 
differences in activation time points of that diode (determined from dF/dt)max) and its 8 nearest 
neighbours, as previously described.
77
 Measurements of duration are expressed as mean  SEM; 
Student’s t –Test (unpaired) was applied to determine statistical significance based on p < 0.05. 
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3.3.4 Mathematical modeling 
Experimental studies have shown that dauricine inhibits the late sodium current, INa (IC50 
= 46 µM),
64
 the delayed potassium rectifier current, IKr (IC50 = 14 µM)
65
 and the L-type Ca
2+
 
current, ICa,L.
65
 The effect of dauricine on ICa,L is complex. In ventricular myocytes, dauricine has 
been shown to inhibit the peak ICa,L by 23.2%, 36.3%, and 46.0%, at 1, 3, and 10 µmol/L, 
respectively.
78
 At 10 µM, dauricine shifted the steady state activation curves to the right (by +8 
mV) and the inactivation curves to the left (by -10 mV) thereby reducing the ‘window’ current 
and prolonging the recovery time from inactivation.
78
 
The Shannon model 
79
 was used to study the effect of dauricine based on it’s closer fit to 
experimental data.
80
 The whole cell model was compiled in MATLAB and mathematical 
formulation to study the gating parameters of ICa,L was compiled in a platform provided by Dr. 
Jose Luis Puglisi. LQT2 condition was modelled under bradycardia and reduced repolarization 
reserve by inhibition of IKr by 50%, elevation of ICa,L by 32% in addition to decrease in V0.5Act to 
-24.5 mV as reported earlier.
80
 In order to mimic the effect of dauricine (5 µM) on the ICa,L, the 
V0.5Act and the V0.5Inact potential were shifted by +5 mV (from -24.5 mV to -19.5 mV) and -5 
mV (from -35.06 mV to -40.06 mV) respectively, thereby reducing the ‘window’ current. In 
order to study the effect of voltage dependent activation/inactivation parameters and reduce the 
effect of Cai-dependent inactivation, the [Cai] was fixed at 120 nM and KmCa at 0.6 µM. The 
steady state parameters of the ICa,L shown below were modified to assess its effect on 
antiarrhythmic properties where, d = Voltage-dependent activation gate, f = Voltage-dependent 
inactivation gate, τd = Time-constant activation gate and τf = Time-constant inactivation gate 
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Equation 11 
 
 
 
Equation 12 
 
 
 
Equation 13 
 
 
 
 
Equation 14 
 
3.4 RESULTS 
3.4.1 Effect of dauricine on APs and CaiT as a function of cycle length 
Figure 11A illustrates representative traces of optical APs and CaiT from one of the 
pixels on the photodiode array that measured voltage changes and the corresponding pixel on the 
photodiode array that measured Cai from the same site on the heart (0.9x0.9 mm
2
). Figure 11B 
shows corresponding action potential and calcium transient when the heart was stimulated at a 
CL of 300 ms and after addition of dauricine (5 µM). Dauricine did not significantly alter APDs 
and CaiT but it had a tendency to prolong them irrespective of the CL. However, it slowed the 
conduction velocity (CV) significantly (p < 0.05) in a rate independent manner.
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Figure 11: Effect of dauricine in control hearts as a function of rate 
(A) Optical mapping traces of action potential (AP) and calcium (Cai) transients measured from 
the same site in the heart paced at 300 ms CL. (B) Comparison between Vm and CaiT under 
control and when treated with dauricine (5 µM). (C) APD90, CaiT80 and conduction velocity 
changes in the presence of dauricine (5 µM) at 300, 500 and 1000 ms CL. 
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3.4.2 Effect of dauricine under drug-induced LQT2 
Figure 12A shows a sample AP and CaiT trace when the heart was stimulated at a CL of 
1000 ms. Dofetilide (0.5 µM) resulted in prolongation of APD from 318 ± 24 ms to 835 ± 32 ms 
(p < 0.01) and CaiT from 346 ± 36 ms to 867±48 ms (p < 0.01). Prolongation of the APDs was 
followed by ectopic activity leading to EADs which ultimately developed into TdP (Figure 12B). 
Addition of dauricine to the perfusate in the presence of dofetilide, reduced the dofetilide 
induced APD prolongation from 835 ± 32 ms to 542 ± 93 ms (p < 0.01) and reversed CaiT 
prolongation from 867 ± 48 ms to 567 ± 103 ms (p < 0.01). Dauricine not only reversed 
prolongation but also suppressed EADs, elicited by dofetilide (n = 5/5 hearts; p < 0.01) (Figure 
12C). When dauricine was washed out, while the heart was still exposed to dofetilide, in 5 min 
the prolongation of APD and CaiT became more pronounced leading to Cai instabilities, EADs 
and eventually TdP (Figure 12D).   
Figure 13 shows a schematic of the heart and the area optically mapped by a 16x16 
photodiode array (top panel) and repolarization maps generated using our custom built IDL 
software.
81, 82
 Under control conditions, the repolarization sequence exhibited a standard trend 
from the apex to the base of the heart. Repolarization started at the apex 240 ms after the ﬁrst site 
to activate and the last site repolarized at 366 ms, with the APDs at the base being considerably 
longer than that at the apex (329 ± 24 ms compared to 304 ± 26 ms). Dofetilide reversed the 
direction of repolarization pattern from apex to base became base to apex and also increased 
DOR from 25 ± 6 ms to 55 ± 15 ms (p < 0.01 vs Control). The ﬁrst and last regions to repolarize 
occurred, respectively, 700 ms and 900 ms after the ﬁrst site to activate. When dauricine was 
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added in the presence of dofetilide, it reversed the repolarization pattern back to that measured in 
the control condition (apex→base) and also reduced the dofetilide-induced dispersion of 
repolarization from 55 ± 15 ms to 29 ± 15 ms (p < 0.05 vs Dofetilide only). Table 3 summarizes 
the effect of dofetilide and dauricine. 
 45 
 
Figure 12:  Dauricine suppresses EADs and TdP in drug-induced LQT2 
Representative AP and CaiT traces under (A) Control at 1000 ms CL; (B) 8 mins after 
the addition of dofetilide (0.5 µM); (C) 5 mins after the addition of dauricine (5 µM) in 
the presence of dofetilide (0.5 µM); (D) 7 mins after the washout of dauricine (5 µM). 
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Figure 13: Effects of dofetilide and dauricine on repolarization patterns 
A schematic of the heart with the area optically mapped (Top). Under Control, the 
repolarization sequence exhibited the standard sequence from apex to base (white arrows, 
left panels). Dofetilide (0.5 µM) reversed the repolarization sequences (white arrows; middle 
panels) and increase the dispersion of repolarization. Dauricine (5 µM) in the presence of 
dofetilide reversed the repolarization sequence (white arrows; right panel) and also reduced 
the dispersion of repolarization.  
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Table 2: Summary of Parameters - Effect of dofetilide and dauricine 
* versus Control p < 0.01; ! versus Dofetilide p < 0.01; ‡ versus Dofetilide p < 0.05 
 
 
 
 
 
 APD90 (ms) CaiT (ms) DOR (ms) 
Control (n = 5) 318 ± 24 346 ± 36 25 ± 6 
Dofetilide (n = 5) 835 ± 32 * 867 ± 48* 55 ± 15* 
Dofetilide + Dauricine  
(n = 5) 
542 ± 93 ! 567 ± 103 ! 29 ± 15 ‡ 
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3.4.3 Modeling: Effect of dauricine under LQT2 
LQT2 conditions resulted in Ca
2+
 overload, spontaneous SR Ca
2+
 release and EADs. The 
APs had single or multiple EADs in each beat (287 EADs in a train of 200 APs). Modeling the 
effect of dauricine on the INa,Late and IKr did not suppress the arrhythmias. Incorporating the 
effects of dauricine on the V0.5Act and V0.5Inact of ICa,L resulted in (a) smaller ICa,L ‘window’ 
current (Figure 14A); (b) partially reversed the APD back to control conditions (448 ms to 240 
ms compared to 226 ms in Control); (c) reduced Ca
2+
 overload and (d) abolished the EADs 
(0/287 in 200 beats) (Figure 14B). 
3.4.4 Modeling: Half activation/inactivation potential and arrhythmias 
Although the overall effect of dauricine on the changes in the activation-inactivation 
kinetics suppressed EADs, it was still unclear whether changes to either the voltage-dependent 
activation or inactivation potential would be sufficient to suppress arrhythmias. To elucidate the 
relative importance of activation and inactivation on the incidence of EADs, the V0.5Act (or 
V0.5Inact) was changed in a stepwise manner by ± 1 mV and then in steps of ± 2.5 mV keeping 
the other parameter constant. 
 When the V0.5Act was subjected to a stepwise change, at +1 mV shift from -24.5 
mV to -23.5 mV (Eqns 11, 12), the APD shortened from 448 ms to 385 ms and the peak Cai 
amplitude was reduced from 0.75 µM to 0.72 µM. This shift in V0.5Act was not effective at 
suppressing EADs; there were 172 EADs in 200 beats compared to 287 in 200 beats with normal 
V0.5Act. Stepwise change of +2.5 mV from -24.5 mV to -22 mV shortened the APD further to 
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252 ms, reduced the peak Cai amplitude to 0.42 µM and completely abolished EADs. Additional 
change of +2.5 mV to -19.5 mV resulted in further shortening of the APD to 241 ms and 
reduction of peak Cai amplitude to 0.40 µM (Figure 15). 
When V0.5Inact was subjected to similar stepwise change, a -1 mV shift from -35.06 mV 
to -36.06 mV (Eqns 13, 14) shortened the APD from 448 ms to 413 ms, reduced peak Cai 
amplitude from 0.75 µM to 0.46 µM but did not completely abolish the EADs (142 EADs in 200 
beats compared to 287 in 200 beats). A stepwise change by -2.5 mV to -37.56 mV and -40.06 
mV resulted in shortening of APD to 259 ms and 257 ms respectively, reduced peak-Cai 
amplitude to 0.43 µM and 0.42 µM respectively and completely abolished the EADs (Figure 16). 
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Figure 14: Modeling the antiarrhythmic effects of dauricine under LQT2 
(A) Schematic of the steady state activation/inactivation curves under LQT2 and with 
LQT2 + Dauricine (5 µM). Dauricine shifted the V0.5Act to the right and V0.5Inact to the 
left and reduces the ICa,L ‘window’ current. (B) Shows AP and CaiT from the Shannon 
whole cell rabbit ventricular myocyte model under control, LQT2 and LQT2 + dauricine 
(5 µM). Only the effects of dauricine on the V0.5Act and V0.5Inact were incorporated into 
the model (Eqns 11-14). Dauricine completely abolished the EADs and reversed back the 
AP prolongation in agreement with the experimental results.  
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Figure 15: Modeling the effect of V0.5Act on arrhythmias 
(A) Steady state activation/inactivation curves when V0.5Act was shifted to the right in steps of 
+1 mV and +2.5 mV while keeping V0.5Inact constant, resulted in the reduction of the 
‘window current’ (B) Sample action potential and CaiT traces incorporating the changes in 
V0.5Act in the whole cell model. A +2.5 mV shift effectively suppressed arrhythmias and 
reduced the Ca
2+
 overload. (C) Action potential duration (APD) as a function of the V0.5Act. 
(D) Suppression of EADs as a function of the V0.5Act. 
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Figure 16: Modeling the effect of V0.5Inact on arrhythmias 
(A) Steady state activation/inactivation curves when V0.5Inact was shifted to the left in steps of -
1 mV and -2.5 mV while keeping V0.5Act constant, resulted in the reduction of the ‘window 
current’ (B) Sample AP and CaiT traces with the changes in V0.5Inact in the whole cell model. 
A -2.5 mV shift effectively suppressed arrhythmias and reduced the Ca
2+
 overload. (C) Action 
potential duration (APD) as a function of the V0.5Inact. (D) Suppression of EADs as a function 
of the V0.5Inact. 
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3.5 DISCUSSION 
The main results are that in control hearts, dauricine (5 µM) slowed CV in a rate independent 
manner. In drug-induced LQT2, dauricine suppressed EADs and TdP in the presence of an IKr 
blocker (dofetilide). Mathematical modeling confirmed that dauricine suppressed the EADs and 
reversed the AP prolongation primarily by slowing down the kinetics of ICa,L, specifically by 
decreasing the V0.5Act, increasing the V0.5Inact and thereby decreasing the ‘window’ current. 
Simulation also revealed that a minor change of ± 2.5 mV in either of the V0.5Act or V0.5Inact is 
sufficient enough to abolish EADs.  
  Dauricine has been demonstrated to be a promising anti-angiogenic drug for the treatment 
of human breast cancer mainly via the suppression of HIF-1α and by blocking the PI-
3K/Akt/mTOR signaling pathways.
67
 It has also been shown effective in suppressing colon 
cancer mainly via the down regulation of NF-κB-mediated gene expressions including genes 
involved with anti-apoptosis and angiogenesis.
83
 In recent years with the success of dauricine in 
suppressing tumours and with the promise of entering clinical trials as a treatment for cancer, 
tremendous amount of work has been done to assess its effects on the heart.  
In our study, dauricine had a tendency to prolong APD and CaiT under control conditions 
at different CL. This can be attributed to the tendency of dauricine to inhibit IKr and IKs currents 
in a rate independent manner.
63, 84
 On the other hand, dauricine significantly reversed dofetilide-
induced APD and CaiT prolongation. Dispersion of repolarization (DOR) has been implicated as 
an important risk factor in the initiation and maintenance of arrhythmia in the LQTS.
85
 Our study 
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showed that the effect of dofetilide was greater at the apex than the base due to the gradient of IKr 
resulting in a reversal of the direction of repolarization and a marked increase in DOR. However, 
the presence of dauricine with dofetilide reversed this direction of repolarization back to control 
and also reduced the DOR. Simulations with the effects of dauricine (5 µM) on V0.5Act or 
V0.5Inact under LQT2 completely suppressed EADs. A ± 1 mV shift in either the V0.5Act or 
V0.5Inact resulted in suppression of EADs with an efficiency of 40% and 50% respectively. 
Changes by ± 2.5 mV in either of the parameters resulted in a complete suppression of EADs. 
Our studies demonstrate the antiarrhythmic properties of dauricine in LQT2 syndrome in whole 
hearts and simulations. Similar actions of the drug could be responsible for antiarrhythmic 
properties and efficacy in pathology such as or Timothy syndrome, also known as LQT8 or 
syndactyly-associated LQTS. Timothy syndrome is associated with missense mutations in the 
Cav1.2 gene that lead to a marked loss of voltage-dependent inactivation resulting in a gain of 
function of ICa,L.
86
 Increased activity of L-type Ca
2+
 channels may lead to Ca
2+
 overload in the 
cell, which has been shown to contribute to the development of EADs and TdP.
87, 88
  
The L-type Ca
2+
 channel in the heart (Cav1.2) is composed of four subunits, including α1, 
α2δ, β and γ. The α1-subunit forms the pore of the channel. The co-expression of α2δ increases 
the membrane trafficking along with an increase in current amplitude, faster activation and 
inactivation kinetics, and a hyperpolarizing shift in the voltage dependence of activation.
89
 The 
β-subunit aids in trafficking of the α1-subunit to the membrane and the α1-β interaction is known 
to modulate the biophysical properties of the channel such as current density and the properties 
of activation and inactivation.
75, 89
 The γ predominantly modulates the biophysical properties of 
the channel.
89
 Each of the three major types of selective Ca
2+
 channel blockers (benzothiazapine 
(diltiazem), phenylalkylamine (verapamil) and dihydropyridines (nifedipine)) interacts with a 
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specific receptor domain located on the α1-subunit that constitutes a substantial portion of the 
Cav1.2 and can modulate other receptor sites.
75, 90
  
Based on previous computational and experimental work, researchers have tried to 
modulate the subunits and studied its effect on arrhythmogenesis and cardiac wave stability.
91
 
Their results indicate that the recovery kinetics of the ICa,L current were relatively insensitive to 
β-subunits but changed dramatically when β-subunits were eliminated and along with the 
reduction in the amplitude of ICa,L flattened the restitution.
91
 In another study, mutant Ca-
insensitive calmodulin CaM1234 were over expressed in isolated rabbit ventricular myocytes to 
alter ICa,L inactivation kinetics and increase dynamic wave stability, by flattening APD restitution 
slope and preventing APD and CaiT alternans, without decreasing contractility.
68
 Although, these 
studies provide theoretical strategies and genetic modification to suppress arrhythmias, no one 
has reported on a known natural or formulated therapeutics that modulates the kinetics of the 
ICa,L and suppresses arrhythmias. 
3.6 LIMITATIONS 
Blocking ICa,L, by reducing the channel conductance is a potent means of suppressing 
arrhythmias, but unfortunately the dose of Ca
2+
 channel blocker required to achieve this effect 
suppresses contractility. Dauricine at therapeutic doses (5-10 µM) reduces the ICa,L ‘window’ 
current and the influx of Ca
2+
 with each beat, thereby suppressing contractility. No direct 
measurements have been made in the study to assess contractility changes. In the late 80’s, 
dauricine (~180 mg) was clinically evaluated in treating cases of arrhythmias in humans with an 
efficiency of 91.3% and the contractility changes seem to be tolerated.
92
 Cases of QT 
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prolongation and complete left bundle branch block have also been reported with regard to a 
treatment with dauricine but at a higher dose of 900 mg/day.
93
  
Another potential drawback of the study is the lack of information regarding the binding 
site of dauricine to ICa,L. Although, most of the Ca
2+
 blockers bind to α1-subunit and induce a 
decrease in conductance of ICa,L, the effect of dauricine is more intricate. Dauricine has also been 
shown to shift the inactivation curve to the right and markedly delayed the half-recovery time of 
ICa,L from inactivation.
78
 Further studies are needed to assess dauricine’s binding site, whether or 
not it modulates the interaction between the subunits, and to relate its structure-function 
relationship to its antiarrhythmic effects. Based on binding site information, a relatively large 
number of derivatives of dauricine can be designed to bind and modulate channel kinetics my by 
analogy with studies based on the family of dihydropyridine derivatives.
90, 94
 
3.7 CONCLUSION 
The findings from our experimental and simulation studies provide evidence of 
dauricine’s antiarrhythmic property based on channel kinetic modification which represents a 
novel strategy to suppress arrhythmias. In summary, our findings support the existing theoretical 
studies, provide novel insight on the mode of action of dauricine’s antiarrhythmic properties, 
how minor changes in half-activation (V0.5Act) and half-inactivation potential (V0.5Inact) of L-
type Ca
2+
 channel can effectively suppress EADs and a foundation for further studies to design 
analogues of dauricine that can suppress arrhythmias without affecting contractility.  
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4.0  RELAXIN MITIGATES INDUCED ATRIAL FIBRILLATION (AF) IN 
SPONTANEOUSLY HYPERTENSIVE RATS (SHR) BY REVERSAL OF FIBROSIS 
4.1 SPECIFIC AIMS 
Atrial fibrillation (AF) is the most common form of cardiac arrhythmia and contributes 
significantly to cardiac morbidity and mortality. AF has been associated with fibrosis, aging, and 
hypertension. Pharmacological therapy targeted at the underlying fibrotic substrate has claimed 
to be a new frontier in the management of AF.  
Aim 1: To test the hypothesis that atrial fibrosis is a key factor in the genesis of 
induced AF in spontaneously hypertensive rats (SHR) 
The mechanisms of AF were elucidated using SHR hearts as models of hypertension, 
fibrosis and AF. SHR and normotensive Wistar Kyoto (WKY) were tested for inducible AF with 
programmed stimulation applied to the right atrium (RA) and optically mapped for APs and 
CaiT. The nature of AF was determined through measurements of dispersion of repolarization 
(DOR), Cai instabilities, changes in restitution kinetics (RKs: AP durations, CV and rise times of 
Cai and AP upstrokes). Immuno-histological analysis of atrial tissues correlated fibrosis, 
connexin (40/43) levels and AF induction between SHR and WKY. 
Aim 2: To test the hypothesis that exogenous relaxin (RLX) treatment mitigates AF 
inducibility 
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The mechanisms whereby RLX treatment mitigates AF inducibility was elucidated using 
SHR. SHR rats were treated with RLX or vehicle for 2 weeks and the hearts were tested for 
inducible AF with programmed stimulation applied to the right atrium (RA). Changes in 
restitution kinetics were compared between the RLX-treated and vehicle-treated groups (RKs: 
AP durations, CV and rise times of Cai and AP upstrokes). Histological analysis of atrial tissues 
correlated fibrosis levels, connexin (40/43) levels/phosphorylation and localization and AF 
induction between untreated, RLX-treated and vehicle-treated SHR.  
4.2 INTRODUCTION 
Atrial Fibrillation (AF), the most commonly encountered arrhythmia, affects about 2.3 
million people in the United States and is a leading cause of stroke and heart failure. 
95
 The cost 
of AF and its associated complications equaled $12 billion in 2006. 
96
 
 Among the many risk factors that have been proposed for the development of AF, 
the most important risk factors are sex (males compared to females), old age (age >60 years), and 
hypertension.
95
 Hypertension leads to both electrical and structural remodeling of the atria. 
Electrical remodeling shortens atrial refractoriness by reducing the APD. 
97, 98
 Atrial tachypacing 
(≥300 beats/min) causes remodeling as demonstrated in dogs, sheep and pigs and has been 
associated with rate-induced Ca
2+
 overload, transcriptional down regulation of L-type Ca
2+
 
channels, shortening of APD, and spontaneous opening of acetylcholine-regulated K
+
 channels.
99
 
Chronic AF (CAF) leads to further remodeling including; increased expression of protein kinase 
C (PKC) and PKC-dependent protein phosphorylation, Ca
2+
-calmodulin dependent kinase II 
(CaMKII) activation, phosphorylation of ryanodine receptors (RyR2), greater spark activity, 
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spontaneous Ca
2+
 release from the sarcoplasmic reticulum and a greater incidence of early and 
delayed afterdepolarization.
100
 Thus, changes in Ca
2+
 handling contribute to the severity of AF in 
patients with chronic 
101-103
 and paroxysmal AF.
104
 Long-term rate-dependent remodeling may 
lead to decrease in CV due to down regulation of Nav1.5 and INa,
105, 106
 and to a reduction and 
lateralization of gap junctions, mainly connexin 43 even though connexin 40 is also abundant in 
the atria of some speices.
107
 
Connexin act as a low resistance intercellular pathway for impulse propagation by 
regulating the flow of ions between adjacent cardiac myocytes.
108
 The cardiac myocytes are 
mostly connected via gap junctions located at the narrow ends of the rectangular myocytes. 
Connexin emerges as a molecule that is involved not only in forming gap junctions for the cell–
cell transfer of electrical charge but also as an organization center for the establishment of proper 
sodium channel function.
109
 Fibrosis is the hallmark of arrhythmogenic structural remodeling.
110
 
Fibrosis can be due to cell death when these cells are replaced by collagen, called reparative 
fibrosis, or to aging without cell loss or increases in mechanical load, which is called reactive 
fibrosis.
111, 112
 It results in alterations in the connexin expression
113
 and creates a barrier to 
impulse propagation by disrupting inter-myocyte coupling.
110,114
 Structural remodeling also 
results in electrical tissue non-homogeneity, slowed conduction and electrical uncoupling, 
facilitating AF continuation without inducing changes in atrial action potential properties.
115
  
 Increased collagen deposition has been well documented in AF patients compared 
with control subjects in sinus rhythm.
116
 The precise signaling processes responsible for the 
development of fibrosis are unknown. However, multiple factors such as angiotensin converting 
enzyme (ACE), Transforming Growth Factor β (TGF-β1) and Platelet Derived Growth Factor 
(PDGF) have been implicated in the pathogenesis of atrial fibrosis. Studies on ACE 
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overexpression in mice revealed that increased ACE is associated with atrial enlargement, atrial 
fibrosis, and AF.
117
 Conversely, blockade of ACE or angiotensin-receptor blunts atrial fibrosis 
and AF in animal models and patients with HF.
118
 Transforming Growth Factor β (TGF-β1) and 
Platelet Derived Growth Factor (PDGF) are thought to act on cardiac fibroblasts to increase 
collagen production without offsetting increases in collagen degradation.
110
 Similar to studies 
with overexpression of ACE, animal studies with overexpression of TGF-β1, have shown that 
TGF-β1 is associated with increased levels of atrial fibrosis and susceptibility to AF.119 Studies 
with injection of PDGF-α in mice have shown that increased levels of PDGF-α are associated 
with atrial fibrosis and AF in normal hearts. 
120
 
 The current treatment and management options for AF include radiofrequency 
ablation, antiarrhythmic drugs, and anticoagulation therapy. Even though radiofrequency 
ablation has been shown to be more effective than antiarrhythmic drugs for treatment of 
paroxysmal AF, the complications, costs, and difficulties (i.e. recurrence of AF) serve as the 
driving force for the development of better and safer therapies for the treatment of AF.
121, 122
 
Existing antiarrhythmic drug approaches have limited effectiveness and are associated with risks 
of serious complications, particularly ventricular pro-arrhythmia and/or organ toxicity.
123
 
Accordingly, attenuation and reversal of structural remodeling have increasingly become the 
focus of attempts at therapeutic innovation, and is of particular clinical interest because it is often 
not possible to begin treatment in humans before a significant degree of atrial remodeling 
has already occurred and is irreversible.  
Relaxin (RLX), a peptide hormone, is thought to have a wide range of biological actions 
including anti-inflammatory, anti-apoptotic, cardioprotective, vasodilatory, pro-angiogenic 
effects, and anti-fibrotic effects.
124
 RLX was first identified for its role in reproduction and 
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pregnancy. It is thought to play a critical role in the hemodynamic adaptive and anti-fibrotic 
changes that occur during pregnancy.
125
 Our hypothesis is that RLX’s anti-fibrotic properties 
may be effective in the suppression of fibrosis AF. Male RLX gene-deficient mice developed 
age-related cardiac fibrosis, ventricular stiffening, and diastolic dysfunction, suggesting its role 
as an important intrinsic regulator of collagen turnover.
126
 Studies on RLX treated spontaneously 
hypertensive rats (SHR) have shown its effectiveness in reversing fibrosis in the ventricles. 
However, the study did not see a difference in atrial fibrosis between RLX treated SHR and 
saline treated SHR.
127
 Therefore, RLX’s potential application in the reversal of atrial fibrosis and 
suppression of AF is not known.   
There is no such thing as a ‘perfect’ animal model of AF, any more than there is a single 
clinical mechanism of AF. Any animal model reproduces at best a very limited component of the 
pathophysiologic spectrum of clinical AF.
128
 The most widely studied model for the effects of 
hypertension on the cardiovascular system is the SHR.
129
 In SHR, hypertension progresses as a 
function of age, is more pronounced in males than females, and exhibits most of the hallmarks of 
the human disease.
130
 Previous studies on the SHR model have shown an increased incidence of 
AF and atrial tachyarrhythmias compared to normotensive Wistar-Kyoto (WKY), attributed to 
greater fibrosis levels.
131
 These findings indicate that fibrosis is a key factor promoting the 
development of AF making it an important antiarrhythmic target. 
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4.3 METHODS 
4.3.1 Study design 
Age (9-12 months) and sex (male) matched rats were divided into four groups WKY, 
SHR, SHR treated with vehicle (SHR+VEH) and SHR treated with relaxin (SHR+RLX) to test 
for AF inducibility. Subcutaneous osmotic minipumps (Ducruet Corporation, model 2ML2) were 
primed and loaded with either recombinant human RLX solution (release rate: 0.4 (mg/kg)/day) 
or VEH (20 mmol/L sodium acetate buffer, pH 5.0). RLX was obtained from Corthera Inc. This 
dose of RLX was modified to accommodate the reservoir volume of the mini-pumps and is 
slightly lower than the 0.5 (mg/kg)/day that have been used previously to treat in vivo rodent 
models of fibrosis.
127, 132-134
 Pumps were surgically implanted under sterile technique into the 
subcutaneous space on the left side of anesthetized animals. Animals were monitored over the 
14-days of RLX or VEH delivery to ensure proper healing of the implant pocket.  
4.3.2 Blood pressure, heart rate and serum relaxin concentration 
Blood pressure (BP) was measured by a noninvasive tail cuff method using Coda 6 (Kent 
Scientific Corp., Torrington, CT), which measured heart rate (HR) and systolic and diastolic 
pressures.
135
 Signals were recorded and analyzed using Kent Scientific software. The BP and the 
HR were measured at three different time points during the 14-day treatment period with either 
RLX or vehicle; pre-treatment, mid-treatment (6-9
th
 day of a 14-day treatment) and post-
treatment (14
th
 day). Blood samples were taken immediately after the hearts were excised to 
measure RLX serum concentration. Quantikine Human Relaxin-2 Immunoassay (DRL200, R&D 
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Systems Inc., Minneapolis, MN, USA) was used according to the manufacturer’s protocol to 
determine the serum RLX concentration of the samples. 
4.3.3 Optical apparatus and analysis 
Hearts were excised from animals of either strain and treatment protocol after being 
anesthetized with pentobarbital (50 mg/kg) and injected with heparin (200 U/kg IV). Coronary 
arteries were perfused via the aorta in a Langendorff perfusion system with physiological Tyrode 
solution containing (mM): 122 NaCl, 25 NaHCO3, 4.81 KCl, 2 CaCl2, 2.75 MgSO4, 5 Glucose 
(pH 7.4) gassed with 95 percent O2 and 5 percent CO2 at 37.0±0.2 degrees Celsius. 
 Hearts were placed in a chamber and initially perfused with 30 µL blebbistatin to 
arrest contractions and reduced motion artifacts. The hearts were stained with bolus injections of 
a voltage-sensitive dye (PGH-1; 300 µL of 1mg-ml
-1
 in dimethyl sulfoxide, DMSO) and Ca
2+
 
indicator (Rhod-2/AM, 300 µL of 1mg-ml
-1
 in DMSO) or only the voltage-sensitive dye (di-4-
ANEPPS 10 µL of 2 mmol/L in DMSO) to optically map action potentials with the anterior 
surface of the heart. 
Light from two 100-W tungsten-halogen lamps was collimated, passed through 520 ± 30 
nm interference filters, and illuminated the heart from two sides for uniform illumination. 
Fluorescence emitted from the stained heart was collected with two camera lenses (50 mm f/1.2 
mm Nikon and 50 mm f/0.95 Navitar) on two 100 x 100 pixel CMOS cameras (Ultima, 
Scimedia, Ltd. Tokyo, Japan) scanned at 2,000 frames per second. Pixel resolution was 150 x 
150 µm
2
, and the data was recorded and stored in intervals of 4-8 seconds.   
 The activation and repolarization time points at each site were determined from 
fluorescence (F) signals by calculating (dF/dt)max and (d
2
F/dt
2
)max, which has been shown to 
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coincide with ~97% repolarization to baseline and recovery from refractoriness.
76
 Local CV 
vectors were calculated for each pixel from the differences in activation time-points of that pixel 
(determined from (dF/dt)max) and its 7 × 7 nearest neighbors, as previously described.
76
 Local 
conduction velocities were averaged and represented as means ± standard deviation. Local CV 
can be overestimated when two wave fronts collide, transmural conduction occurs, or near the 
stimulation site where a small area of tissue was stimulated simultaneously. To correct this error, 
CVs greater than 1.0 m s
−1
 were removed from mean/standard deviation statistics. 
136
 In order to 
minimize the error propogation, the APDs were averaged over 10 beats from each pixel over 7 
pixels and the CVs vectors were averaged over 10 individual local vectors. 
4.3.4 Programmed stimulation 
In order to test the vulnerability of hearts for AF, each of the hearts in the study was paced at the 
RA using programmed stimulation protocol consisting of 20 S1 pulses at 250 ms followed by a 
premature S2 pulse with a systematically shorter S1-S2 interval (250 ms, 200-100 ms (steps of 20 
ms), 100-60 ms (steps of 10 ms), 60-35 (steps of 5ms)) until loss of capture or AF was induced. 
4.3.5 Immuno-histology 
RA and LA samples from the optically mapped hearts of the different groups were 
cryostat preserved, sectioned into tissue 5-6 microns thick, and mounted onto gel-coated glass 
slides. Slides were kept at –20 C until they were studied for immunohistochemistry. Tissue was 
rehydrated with  washes of 1X PBS, 0.5% BSA blocking buffer, incubated with 2% BSA 
solution, and again washed with 0.5% BSA blocking buffer. They were then incubated with 
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primary antibody Collagen 1 (Chemicon 1:1000 diluted in BSA). Then tissue sections were 
washed with 0.5% BSA and then incubated with secondary antibody Cy3 diluted in BSA. After 
treatment with secondary antibody, slides were sequentially rinsed with 0.5% BSA blocking 
buffer and PBS before nuclei were labeled with Hoechst 33342 (Sigma).  Slides were viewed 
with an Olympus (Melville, NY) Provis AX70 fluorescent miscroscope at 20X magnification. 
Images were collected with a cooled charge-coupled device camera (Optronics Magnifier; East 
Muskogee, OK) at a 12-bit gray depth and assembled (Adobe Photoshop; San Jose, CA). 
Fractional area of collagen 1 was analyzed using Metamorph software (Molecular Devices; 
Sunnyvale, CA).  
4.3.6 Statistics 
AF vulnerability between the different groups was compared using Fisher’s exact test.  
Data are presented as mean ± standard deviation and parameters recorded under different S1-S2 
were compared by ANCOVA. The results were considered significant for p < 0.05.  
4.4 RESULTS 
4.4.1 Atrial fibrillation inducibility 
The vulnerability of the hearts to AF was tested in the different groups using programmed 
stimulation. In WKY hearts, a premature S1-S2 did not induce sustained AF (n = 0/4) (Figure 17 
 66 
a, b), whereas in SHR hearts a premature S1-S2 = 55-75 ms induced transient AF that progressed 
to sustained AF (n = 5/5, p < 0.01 vs WKY) (Figure 17 c, d, e, f).  
 
4.4.2 Optical mapping of atrial fibrillation 
Figure 18 illustrates AP and CaiT from an SHR heart before and during S1-S2 induced 
AF. In all cases, Cai followed Vm, and Cai abnormalities did not precede AF (n = 3/3 hearts), 
unlike our previous reports regarding the initiation of EADs in Long QT syndrome 2 (LQT2).
4, 5
 
Activation maps exhibited a single reentrant circuit (Figure 19A) during the initiation of AF. 
Multiple daughter wavelets were created and annihilated during sustained AF (Figure 19B). 
Furthermore, during sustained AF, the right atrial (RA) dominant frequency (13.7 ± 1.4 Hz) was 
not significantly different from the left atrial (LA) dominant frequency (14.2 ± 0.8 Hz) (Figure 
18D).  
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Figure 17: Inducibility of AF in normotensive and hypertensive rats 
Representative action potential traces from the LA in normotensive WKY rats at (A) S1-S2 interval of 
50 ms; (B) Application of earlier premature impulse at S1-S2 = 45 ms, results in loss of capture of S2. 
Representative action potential traces from LA of SHR rats (C) S1-S2 = 75 ms; (D) Initiation of non-
sustained AF after earlier application of premature impulse at S1-S2 = 70 ms; (E) Induction of 
sustained AF at S1-S2 = 60 ms; (F) Zoomed in AP trace during sustained AF. 
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Figure 18: Role of Cai in AF inducibility 
Superposition of AP and CaiT from LA of SHR. Blue lines indicate a change in the Vm signal 
while red lines indicate a change in Cai signals during (A) S1-S2 = 60 ms; (B) during the initiation 
of sustained AF at S1-S2 = 55 ms. 
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Figure 19: Analysis of the AF 
(A) Activation pattern on a 100x100 pixel CMOS with spatial resolution of 150x150 µm
2
 
exhibiting a single reentrant circuit during non-sustained AF. (B) Activation pattern illustrating the 
creation and annihilation of multiple daughter waves (wavebreaks) during sustained AF. (C) Time-
frequency analysis of AF. The spectrogram was calculated by sliding a 1.5-second Gaussian 
window over normalized optical traces. Top, Optical trace. Left, Overall FFT spectra. Contour 
map, spectrogram with isolines drawn every 12.5% of maximum. Spectrogram plots frequency 
(ordinate) versus time (abscissa) and is shown for 14 seconds of AF; the darker the color, the 
higher the energy density at that frequency. (D) Histogram represents the dominant frequencies 
during sustained AF in SHR rats in the LA and the RA.  
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4.4.3 In-vivo relaxin concentration and its effect on hemodynamic parameters 
After 2 weeks of treatment, serum RLX concentration was significantly greater in 
SHR+RLX (p < 0.001) (Figure 19) compared to SHR+VEH. There were no significant 
differences in pre-treatment, mid-treatment (1 week), and post-treatment (2 weeks) tail blood 
pressure (BP) measurements (Table 4) between SHR+RLX and SHR+VEH (pretreatment: 154.3 
mmHg for SHR+RLX vs. 164.5 mmHg for SHR+VEH, p = NS; mid-treatment: 156.3 mmHg for 
SHR+RLX vs. 164.6 for SHR+VEH, p = NS; post-treatment: 172.8 mmHg for SHR+RLX vs. 
163.9 mmHg for SHR+VEH, p = NS). 
 Furthermore, there were no significant differences in heart rate at pre-treatment, 
mid-treatment, and post-treatment between SHR+RLX and SHR+VEH (pretreatment: 426.9 for 
SHR+RLX vs. 398.7 for SHR+VEH, p = NS; mid-treatment: 464.7 for SHR+RLX vs. 399.9 for 
SHR+VEH, p = NS; post-treatment: 483.1 for SHR+RLX vs. 429.6 for SHR+VEH, p = NS). 
There was a significant increase in HR following treatment with relaxin in the SHR+RLX group 
(pretreatment: pretreatment: 426.9 vs. post-treatment: 483.1, p < 0.05).  
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Table 3: Effect of relaxin on hemodynamic parameters 
* versus Pre-TX (SHR+RLX) p < 0.05 
 
Pre-Tx Mid-Tx Post-Tx 
 
SHR+RLX SHR+VEH SHR+RLX SHR+VEH SHR+RLX SHR+VEH 
Tail BP 
(mmHg) 
154.3 ± 6.9 
(10) 
164.5 ± 16.4 
(4) 
156.3 ± 10.4 
(6) 
164.6 ± 1.2 
(3) 
172.8 ± 6.9 
(5)* 
163.9 ± 19.4 
(2) 
HR (BPM) 
426.9 ± 18.3 
(10) 
398.7 ± 26.9 
(4) 
464.7 ± 19.1 
(4) 
399.9 ± 45.1 
(3) 
483.1 ± 11.8 
(5) 
429.6 ± 44.6 
(2) 
Figure 20: Blood Serum Relaxin Concentration 
Blood Serum RLX concentration pre and post treatment in SHR implanted with mini-pumps 
containing either RLX or VEH. 
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4.4.4 Effect of relaxin on AF inducibility 
Treatment with RLX for 2 weeks suppressed AF inducibility in SHR (n = 1/6) (Figure 20 a, b), 
while VEH treatment in SHR failed to suppress AF inducibility (n = 4/4; p < 0.01 vs. 
SHR+RLX) (Figure 20 c, d).  
 
 
Figure 21: Effect of relaxin on AF inducibility in SHR 
Exemplary voltage (Vm) trace of LA of SHR+RLX treated heart (A) Non-sustained AF initiation at 
S1-S2 = 35 ms. (B) Earlier application of the premature impulse at S1-S2 = 30 ms results in loss of 
capture of S2. (C) Representative Vm trace of LA of SHR+VEH treated heart at S1-S2 = 50 ms, 
which initiated sustained AF (D) Vm trace during sustained AF.  
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4.4.5 Action Potential Duration (APD) and Conduction Velocity (CV) restitution 
Atrial differences in APDs and CVs between WKY, SHR, SHR+VEH and SHR+RLX 
are shown in Figure 21. APD in the SHR were significantly shorter then APDs in WKY at the 
RA (p < 0.05) and the LA (p < 0.05). There was no statistical significant between APDs at the 
RA and LA between RLX treated and untreated or vehicle treated SHR. 
 CV measurements revealed a significantly slower CV in the LA of SHR 
compared to WKY (p < 0.01). RLX-treatment increased the LA-CV compared to SHR (p < 
0.05). RA-CV measurements were not significantly different for SHR vs. WKY. RLX-treated 
SHR showed no significant CV compared to SHR and SHR+VEH. 
4.4.6 Histological findings 
Differences in LA and RA fibrosis levels between the different groups are shown in 
Figure 22. SHR had a significantly greater collagen to tissue ratio in both the RA and LA 
compared to WKY (p < 0.05). There was no significant difference in collagen to tissue ratio in 
both the RA and LA between SHR and SHR+VEH. RLX treatment attenuated the fibrosis within 
2 weeks in SHR as SHR+RLX had a significantly lower collagen per fractional area compared to 
SHR and SHR+VEH (p < 0.05).   
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Figure 22: Action Potential Duration (APD) and Conduction Velocity (CV) Restitution kinetics 
(A) Left Atrium (LA) mean APD and Conduction Velocity (CV) measurements as a function of S1-
S2 interval. All values are reported as mean + SD. APD-SHR vs. WKY: p <0.05; APD-SHR+RLX 
vs. SHR p = NS. CV-SHR vs. WKY: p < 0.01; CV-SHR vs. SHR+RLX: p < 0.05 (B) Right Atrium 
(RA) mean APD and CV measurements as a function of S1-S2 interval. All values are reported as 
mean + SD. APD-SHR vs. WKY: p < 0.05; APD-SHR+RLX vs. SHR+VEH p = NS. CV-SHR vs. 
WKY: p = NS; CV-SHR vs. SHR+RLX: p = NS. 
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Figure 23: Fibrotic remodeling of atria and its reversal with relaxin 
(A) LA and RA collagen I expression as percent of fractional area for WKY, SHR, SHR+VEH, 
and SHR+RLX. All values are reported as mean + SD. (B) Representative immuno-histological 
sections at 20X magnification of age-matched male LA of WKY, SHR, SHR+RLX, SHR+VEH. 
Phalloidin is represented in green; Collagen I is shown in red.  
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4.5 DISCUSSION 
4.5.1 Main findings 
In this study, we showed that SHR have higher susceptibility to AF triggered by a 
premature impulse. SHR atria had a slower CV and higher levels of collagen deposition and 
fibrosis. RLX-treatment for 2 weeks significantly reversed fibrosis, increased atrial CV, and 
suppressed the AF phenotype in SHR.  
4.5.2 Atrial fibrosis and AF 
Atrial fibrosis has been implicated in the pathogenesis of AF. Fibrosis was the most 
common finding from histological studies done on the hearts of patients with primary AF.
137
 Our 
histological studies support the notion that hypertension leads to fibrosis mediated structural 
remodeling and an increase in collagen I/III levels. In addition, SHR atria are characterized by 
conduction abnormalities that provide a basis for lines of conductional block and re-entry as seen 
in optical mapping studies. AF can be maintained by either sustained rapid ectopic activity or by 
re-entry. Re-entry depends on the fine balance between the cellular refractoriness and conduction 
velocity. The chances of potential re-entry is increased with a short refractoriness or/and slow 
conduction. Re-entry terminates if refractoriness is prolonged (prolonging APD) or if conduction 
is accelerated, as it encounters tissue that is still refractory and dies out.
138
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 The major pathways that have been proposed for the initiation and maintenance of 
AF are the multiple wavelet theory
139
, focal activity hypothesis
140
 and single circuit reentrant 
theory.
141
 Our optical mapping studies were consistent with an AF generated by the continuous 
annihilation and creation of daughter wavelets that lead to sustained AF which supported the 
multiple wavelet theory as the dominant mechanism of AF in SHR.  
4.5.3 Anti-fibrotic and antiarrhythmic properties of relaxin and its clinical relevance 
Relaxin mediates effects on the cardiovascular system via multiple different pathways. It 
activates a wide range of signaling pathways mostly by interacting with the relaxin family 
peptide receptor 1 (RXFP1), a G protein coupled receptor that leads to an acute elevation of 
cyclic AMP (cAMP) and nitric oxide (NO).
142
 In other studies, RLX has been shown to inhibit 
fibroblast proliferation, differentiation, collagen synthesis, collagen deposition and an increase in 
MMP-2 expression, which most likely contributed to an increase in collagen degradation and a 
decrease in collagen deposition.
143
  
Targeting fibrosis has been done before using ACE inhibitors, ARBs, and a novel 
compound Pirfenidone. However, most of these studies have examined models of heart failure, 
which is less commonly associated with AF than hypertension. Pirfenidone has been shown to 
reverse fibrosis and attenuate AF in a CHF canine model.
144
 With treatment with Pirfenidone, 
they showed reversal of atrial fibrosis and reduced vulnerability of AF after burst pacing but did 
not see a significantly greater increase in atrial CV. In contrast our data shows that low dosage 
treatment with RLX reduces AF inducibility, increases atrial CV and decreases atrial fibrosis 
levels.  
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4.5.4 Efficacy and safety 
RLX has been under clinical trials for acute heart failure with a completed 234-patient 
phase 2 and an ongoing 160-patient phase 3.
145
 Clinical use of RLX has not been associated with 
serious adverse effects and toxicity. Reports have confirmed the safety of RLX infusion in 
humans (upto 960 (µg/kg)/day) and have noted a vasodilatory effect in patients with HF, but 
RLX therapy did not always improve renal functions.
146
 The clinical trials to date have sensibly 
addressed potential benefits of short-term treatment in vasodilation, but have not examined 
whether other pathways mediated by RLX can be exploited to provide therapeutic benefits. 
4.6 LIMITATIONS 
Our studies were done on SHR, which have found to have hypertension similar to 
humans.
147
 However, the structural remodeling of hypertension and mechanisms of AF may be 
different in hypertensive humans compared to SHR. We do not know the amount of time 
required for atrial fibrosis and susceptibility for AF to return following treatment of SHR with 2 
weeks of RLX. We are using a very high dose of RLX in these studies, but we do not know the 
minimum dosage required to reliably prevent AF susceptibility.   
 Phase III clinical study using RLX for the treatment of sclerosis revealed abrupt 
appearance of severe hypertension and renal impairment in a number of the patients who had to 
interrupt active RLX therapy.
148
 These adverse effects of RLX were reported only among 
patients with systemic sclerosis, only a small number of individuals without scleroderma have 
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received treatment with RLX and there needs to be more studies looking at the effect of RLX on 
healthy individuals.  
4.7 CONCLUSION 
SHR had increased levels of atrial fibrosis leading to slower CV and greater AF inducibility 
compared to WKY rats. 2 week treatment of RLX significantly reduced fibrosis, improved CV, 
and attenuated AF inducibility in SHR. In RLX-treated SHR, collagen deposition reversed to 
control levels found in WKY hearts along with an increase in metallo-proteinase 6 and 9 levels 
and an increase in CV (p < 0.01, SHR, SHR+V). This study implicates the relationship between 
fibrosis as the underlying abnormality of myocardial substrate that leads to AF and provides 
compelling evidence that reversal of fibrosis, by drugs such as RLX may provide a novel therapy 
in the management of AF. 
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APPENDIX A 
SYMPATHETIC NERVE STIMULATION GENERATES REGIONAL 
HETEROGENEITIES OF Ca
2+
 TRANSIENTS IN RABBIT VENTRICLES 
Authors: Rajkumar Mantravadi
1, 2
, Ashish Parikh
2
, Bethan Gabris
2
 and Guy Salama
2
. 
1 
University of Leicester, UK, 
2
 University of Pittsburgh, Pittsburgh, PA. Heart Rhythm, Vol 7, 
No. 5, May Supplement 2010, S9. 
Introduction: Higher sympathetic innervation at the base compared to the apex has been 
recognized from anatomical and functional studies using optical mapping of cardiac action 
potentials (AP) during sympathetic nerve stimulation (SNS). SNS increases heart rate and 
reduces AP durations more at the base than the apex resulting in a reversal of repolarization 
gradients and apex-base differences in restitution kinetics. However, the effects of SNS on 
intracellular Ca
2+
 transients (CaiT) across the surface of the intact heart are unknown. 
Methods: Langendorff rabbit hearts were isolated with autonomic nerves, stained with 
voltage sensitive (RH237) and Ca
2+
 indicator (Rhod-2/AM) dyes and were optically mapped at 
normal sinus rate (SR) and during SNS (15V; 15Hz) using an electrode inserted in the spinal 
canal to control sympathetic outﬂow. Cai dynamics were compared for SR vs. SNS and apex vs. 
base by measuring: CaiT durations (90% recovery to baseline), Vm-Cai delay (cross correlation 
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analysis), Risetime (time-to-peak) and peak Cai (ΔCai: % change). Data were expressed as mean 
± SEM and paired t-test with p < 0.05 considered signiﬁcant. 
Results: The ﬁgure summarizes the ﬁndings and shows that SNS produced signiﬁcantly 
shorter Vm-Ca delay, shorter CaiT durations, shorter rise-time but higher peak Cai at the base 
compared to the apex. 
Conclusions: The data provides new insights on the regional effects of SNS on Ca
2+
 
handling and highlights large regional heterogeneities of local Cai properties of the myocardium 
caused by heterogeneities of sympathetic innervation. 
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APPENDIX B 
DAURICINE SUPPRESSES EARLY AFTERDEPOLARIZATIONS AND TORSADE DE 
POINTES IN RABBIT HEARTS WITH LONG QT 2 SYNDROME 
Authors: Ashish A Parikh
1
; Xiao-Yan Yang
2
; Fan-Dian Zeng
2
; Guy Salama
1
 
1
 Cardiovascular Institute, Univ of Pittsburgh, Pittsburgh, PA, 
2
 Pharmacology, Tongji Med 
College, Wuhan, China. Circulation.2011; 124: A8917 
Background: Dauricine (Dau) is a bisbenzylisoquinoline alkaloid derivative isolated 
from rhizome of Mensipermum dauricium DC, a Chinese herb. Dau has been shown to lower 
blood pressure, platelet aggregation, inflammatory response and arrhythmia. Dau has also been 
shown to inhibit the late Na
+
 current, INa,Late, IKrand L-type Ca
2+
 current, ICa,L by shifting the 
steady state inactivation and activation curves and prolonging the  value of recovery. 
Objectives: The multiple targets of Dau make it challenging to explain the suppression 
of early afterdepolarizations (EADs) and Torsade de Pointes (TdP) in drug-induced Long QT 2 
(LQT2) model in rabbit hearts by mapping Action Potential (AP) and Ca
2+
 transients (CaiT) and 
to mathematically model the effect of Dau and explain its possible mode of action. 
Methods: Experimental (Langendorff rabbit hearts labelled with Rhod-2/AM and PGH1 
to simultaneously map Action Potential (AP) and Ca
2+
 transients (CaiT)) and simulations 
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(Shannon et al. model) of rabbit AP and CaiT were used to investigate the effects of Dau (5µM) 
before and after LQT2 induced with Dofetilide (Dofe=0.5 μM) to block IKr. 
Results: In controls, Dau tended to prolong AP durations (APDs), CaiT durations (CTD) 
(p>0.5) but significantly reduced conduction velocity (CV) (p < 0.05; n = 5) in a rate 
independent manner. In LQT2, Dofe prolonged APDs (318 ± 24 ms to 835 ± 32 ms; p < 0.01), 
CTDs (346 ± 36 ms to 867 ± 48 ms; p < 0.01) elicited EADs and TdP that were suppressed by 
Dau (p < 0.01; n = 5/5 hearts). Dau (5 µM) reduced the Dofe-prolongation of APDs (835 ± 32 
ms to 542 ± 93 ms; p < 0.01) and CTD (867 ±4 8 ms to 567 ± 103 ms; p < 0.01) and reversed the 
Dofe-prolongation of Dispersion of Repolarization (DOR) (25 ± 6 to 55 ± 15 ms; p < 0.01; 
reversed 55 ± 15 ms to 29 ± 15 ms; p < 0.05). Simulations of the effects of Dofe, Dau and Dofe 
+ Dau indicate that Dau's suppression of EADs is primarily mediated by reducing the Cai 
overload by modifying the kinetics of ICaL. 
Conclusions: Dau (5 µM) markedly reduced CV and in LQT2 significantly shortening 
APDs, CTDs, reduced DOR and suppressed EADs and TdP. Simulations implicate the slowing 
down of activation and inactivation kinetics of ICa,L as the dominant antiarrhythmic mechanism. 
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APPENDIX C 
RANOLAZINE STABILIZES CARDIAC RYANODINE RECEPTORS: A NOVEL 
MECHANISM FOR THE SUPPRESSION OF EARLY AFTERDEPOLARIZATION AND 
TORSADES DE POINTES IN LONG QT TYPE 2 
Authors: Ashish Parikh, MEng, Rajkumar Mantravadi, MD, PhD, Dmitry Kozhevnikov, MD, 
Michael A. Roche, BS, Yanping Ye, BS, Laura J. Owen, BS, Jose Luis Puglisi, PhD, Jonathan J. 
Abramson, PhD, Guy Salama, PhD, FHRS. Heart Rhythm, Volume 9, Issue 6, Pages 953-960, 
June 2012 
Background: Ranolazine (Ran) is known to inhibit multiple targets, including the late 
Na
+
current, the rapid delayed rectifying K
+
current, the L-type Ca
2+
current, and fatty acid 
metabolism. Functionally, Ran suppresses early afterdepolarization (EADs) and torsades de 
pointes (TdP) in drug-induced long QT type 2 (LQT2) presumably by decreasing intracellular 
[Na
+
]i and Ca
2+
overload. However, simulations of EADs in LQT2 failed to predict their 
suppression by Ran. 
Objective: To elucidate the mechanism(s) whereby Ran alters cardiac action potentials 
(APs) and cytosolic Ca
2+
transients and suppresses EADs and TdP in LQT2. 
Methods: The known effects of Ran were included in simulations (Shannon and Mahajan 
models) of rabbit ventricular APs and Ca
2+
transients in control and LQT2 models and compared 
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with experimental optical mapping data from Langendorff rabbit hearts treated with E4031 (0.5 
μM) to block the rapid delayed rectifying K+current. Direct effects of Ran on cardiac ryanodine 
receptors (RyR2) were investigated in single channels and changes in Ca
2+
-dependent high-
affinity ryanodine binding. 
Results: Ran (10 μM) alone prolonged action potential durations (206 ± 4.6 to 240 ± 7.8 
ms; P <0.05); E4031 prolonged action potential durations (204 ± 6 to 546 ± 35 ms; P <0.05) and 
elicited EADs and TdP that were suppressed by Ran (10 μM; n = 7 of 7 hearts). Simulations 
(Shannon but not Mahajan model) closely reproduced experimental data except for EAD 
suppression by Ran. Ran reduced open probability (Po) of RyR2 (half maximal inhibitory 
concentration = 10 ± 3 μM; n = 7) in bilayers and shifted half maximal effective concentration 
for Ca
2+
-dependent ryanodine binding from 0.42 ± 0.02 to 0.64 ± 0.02 μM with 30 μM Ran. 
Conclusions: Ran reduces Po of RyR2, desensitizes Ca
2+
-dependent RyR2 activation, and 
inhibits Cai oscillations, which represents a novel mechanism for its suppression of EADs and 
TdP. 
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APPENDIX D 
MATLAB CODE FOR SHANNON MODEL 
function rabbit 
%%Modified from Pepe's code 
clear all 
%% Initial conditions 
mo=1.405627e-3; 
ho= 9.867005e-1; 
jo=9.915620e-1;  
do=7.175662e-6;  
fo=1.000681;  
fcaBjo=2.421991e-2; 
fcaBslo=1.452605e-2; 
xtoso=4.051574e-3; 
ytoso=9.945511e-1;  
xtofo=4.051574e-3;  
ytofo= 9.945511e-1;  
xkro=8.641386e-3;  
xkso= 5.412034e-3; 
RyRro=8.884332e-1; 
RyRoo=8.156628e-7;  
RyRio=1.024274e-7;  
NaBjo=3.539892; 
NaBslo=7.720854e-1;  
TnCLo=8.773191e-3;  
TnCHco=1.078283e-1;  
TnCHmo=1.524002e-2;  
CaMo=2.911916e-4;  
Myoco=1.298754e-3;  
Myomo=1.381982e-1; 
SRBo=2.143165e-3;  
SLLjo=9.566355e-3;  
SLLslo=1.110363e-1;  
SLHjo=7.347888e-3;  
SLHslo=7.297378e-2;  
Csqnbo= 1.242988; 
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Ca_sro=0.7*5.545201e-1;  
Najo=8.80329;  
Naslo=8.80733;  
Naio=8.80853;  
Kio=135;  
Cajo=1.737475e-4;  
Caslo= 1.031812e-4;  
Caio=8.597401e-5;  
Vmo=-8.556885e+1;  
rtoso=0.9946;  
% Gating variables       
%   1       2       3       4       5       6       7       8       9       10      11      12      13 
%%   m       h       j       d       f       fcaBj   fcaBsl   xtos    ytos    xtof    ytof    xkr     xks    
%y10=[1.2e-3;0.99;   0.99;   0.0;    1.0;    0.0141; 0.0141;     0;      1;      0.0;    1.0;    0.0;    6e-3;]; 
y10=[mo; ho; jo; do; fo; fcaBjo; fcaBslo; xtoso; ytoso; xtofo; ytofo; xkro; xkso;];    
% RyR and Buffering variables 
%   14      15      16      17      18      19      20      21      22      23      24 
%%   RyRr    RyRo    RyRi    NaBj    NaBsl   TnCL    TnCHc   TnCHm   CaM     Myoc    Myom   
y20=[RyRro; RyRoo; RyRio; NaBjo; NaBslo; TnCLo; TnCHco; TnCHmo; CaMo; Myoco; Myomo;];            
%y20=[1;     0;      0;      1.8;   0.8;    0.012;   0.112;  0.01;   0.4e-3; 1.9e-3; 0.135;]; 
% More buffering variables 
%   25      26      27      28      29      30 
%%   SRB     SLLj   SLLsl    SLHj    SLHsl  Csqnb 
y30=[SRBo; SLLjo; SLLslo; SLHjo; SLHslo; Csqnbo]; 
%y30=[3.3e-3; 0.012; 0.012; 0.13;  0.13;  1.5;]; 
%   Intracellular concentrations/ Membrane voltage 
%    31      32      33      34      35      36      37     38       39    40     
%%    Ca_sr   Naj     Nasl    Nai     Ki      Caj     Casl    Cai     Vm    rtos   
y40=[Ca_sro; Najo; Naslo; Naio; Kio; Cajo; Caslo; Caio; Vmo; rtoso; ];     
% y50=[TSao; TSpo; TSwo; TSro; Lo; Lmo; Xpo; Xwo; Fmo]; 
%y40=[0.9;    8.8;    8.8;    8.8;    135;    0.1e-3; 0.1e-3; 0.1e-3; -88;  0.89; 0;          0;]; 
% y50=[UIC3o; UIC2o; UIFo; UIM1o; UC3o; UC2o; UC1o; UOo; UIM2o; LC3o; LC2o; LC1o; LOo ];     
% Put everything together 
y0  = [y10;y20;y30;y40] %;y50];     
%% Single Run Simulation 
tspan = [0;200e3]; 
options = odeset('RelTol',1e-5,'MaxStep',1,'Stats','on');  
[t,y] = ode15s(@f,tspan,y0,options); 
subplot(2,1,1) 
plot(t,y(:,39)) 
subplot(2,1,2) 
plot(t,y(:,38),'r') 
 
d=y(:,4); 
f=y(:,5); 
fcaBj=y(:,6); 
fcaBsl=y(:,7); 
Caj=y(:,36); 
Casl=y(:,37); 
Vm = y(:,39); 
Cai = y(:,38); 
Naj=y(:,32); 
Nasl=y(:,33); 
 
fid=fopen('C:/Documents and Settings/Ashish Parikh/Desktop/2000.txt','w') 
fprintf(fid,' t    vm     cai      d      f     fcaBj    fcaBsl    Caj    Casl   Naj  Nasl\n'); 
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for i=1:length(t)  
 fprintf(fid,'%10.4f  %10.4f  %10.7f  %10.7f  %10.7f  %10.7f  %10.7f  %10.7f  %10.7f  %10.7f  
%10.7f \n', t(i), Vm(i),Cai(i),d(i),f(i),fcaBj(i),fcaBsl(i),Caj(i),Casl(i),Naj(i),Nasl(i)); 
end 
fclose(fid) 
end 
 
%% 
 
function ydot = f(t,y) 
 
ydot = zeros(size(y)); 
 
%% Model Parameters 
% Constants 
R = 8314;       % [J/kmol*K]   
Frdy = 96485;   % [C/mol]   
Temp = 310;     % [K] 
FoRT = Frdy/R/Temp; 
Cmem = 1.3810e-10;   % [F] membrane capacitance 
Qpow = (Temp-310)/10; 
 
% Cell geometry 
cellLength = 100;     % cell length [um] 
cellRadius = 10.25;   % cell radius [um] 
junctionLength = 160e-3;  % junc length [um] 
junctionRadius = 15e-3;   % junc radius [um] 
distSLcyto = 0.45;    % dist. SL to cytosol [um] 
distJuncSL = 0.5;  % dist. junc to SL [um] 
DcaJuncSL = 1.64e-6;  % Dca junc to SL [cm^2/sec] 
DcaSLcyto = 1.22e-6; % Dca SL to cyto [cm^2/sec] 
DnaJuncSL = 1.09e-5;  % Dna junc to SL [cm^2/sec] 
DnaSLcyto = 1.79e-5;  % Dna SL to cyto [cm^2/sec]  
Vcell = pi*cellRadius^2*cellLength*1e-15;    % [L] 
Vmyo = 0.65*Vcell; Vsr = 0.035*Vcell; Vsl = 0.02*Vcell; Vjunc = 0.0539*.01*Vcell;  
SAjunc = 20150*pi*2*junctionLength*junctionRadius;  % [um^2] 
SAsl = pi*2*cellRadius*cellLength;          % [um^2] 
 
J_ca_juncsl = 1/1.2134e12; % [L/msec] = 8.2413e-13 
J_ca_slmyo = 1/2.68510e11; % [L/msec] = 3.2743e-12 
J_na_juncsl = 1/(1.6382e12/3*100); % [L/msec] = 6.1043e-13 
J_na_slmyo = 1/(1.8308e10/3*100);  % [L/msec] = 5.4621e-11 
 
% Fractional currents in compartments 
Fjunc = 0.11;   Fsl = 1-Fjunc; 
Fjunc_CaL = 0.9; Fsl_CaL = 1-Fjunc_CaL; 
 
% Fixed ion concentrations      
Cli = 15;   % Intracellular Cl  [mM] 
Clo = 150;  % Extracellular Cl  [mM] 
Ko = 5.4;   % Extracellular K   [mM] 
Nao = 140;  % Extracellular Na  [mM] 
Cao = 1.8;  % Extracellular Ca  [mM] 
Mgi = 1;    % Intracellular Mg  [mM] 
 
% Nernst Potentials 
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ena_junc = (1/FoRT)*log(Nao/y(32));     % [mV] 
ena_sl = (1/FoRT)*log(Nao/y(33));       % [mV] 
ek = (1/FoRT)*log(Ko/y(35));         % [mV] 
eca_junc = (1/FoRT/2)*log(Cao/y(36));   % [mV] 
eca_sl = (1/FoRT/2)*log(Cao/y(37));     % [mV] 
ecl = (1/FoRT)*log(Cli/Clo);            % [mV] 
 
% Na transport parameters 
 
GNa=16; 
GNaB = 0.297e-3;    % [mS/uF]  
IbarNaK = 1.90719;     % [uA/uF] 
KmNaip = 11;         % [mM] 
KmKo = 1.5;         % [mM] 
Q10NaK = 1.63;   
Q10KmNai = 1.39; 
 
%% K current parameters 
pNaK = 0.01833;       
GtoSlow = 0.06*1;     % [mS/uF] %0.09 CaMKII 
GtoFast = 0.02*1;     % [mS/uF]  
gkp = 0.001; 
 
% Cl current parameters 
GClCa = 0.109625;   % [mS/uF] 
GClB = 9e-3;        % [mS/uF] 
KdClCa = 100e-3;    % [mM] 
 
% I_Ca parameters 
pNa = 1.5e-8;       % [cm/sec] 
pCa = 5.4e-4;       % [cm/sec] 
pK = 2.7e-7;        % [cm/sec] 
Q10CaL = 1.8;        
 
% Ca transport parameters 
IbarNCX = 9.0;      % [uA/uF]IbarNCX 
KmCai = 3.59e-3;    % [mM] 
KmCao = 1.3;        % [mM] 
KmNai = 12.29;      % [mM] 
KmNao = 87.5;       % [mM] 
ksat = 0.27;        % [none]   
nu = 0.35;          % [none] 
Kdact = 0.256e-3;   % [mM]  
Q10NCX = 1.57;      % [none] 
IbarSLCaP = 0.0673; % [uA/uF](2.2 umol/L cytosol/sec)  
KmPCa = 0.5e-3;     % [mM]  
GCaB = 2.513e-4;    % [uA/uF]  
Q10SLCaP = 2.35;    % [none] 
 
% SR flux parameters 
Q10SRCaP = 2.6;          % [none] 
Vmax_SRCaP = 5.3114e-3;  % [mM/msec] (286 umol/L cytosol/sec) 
Kmf = 0.246e-3;          % [mM] default 
%Kmf = 0.175e-3;          % [mM] 
Kmr = 1.7;               % [mM]L cytosol 
hillSRCaP = 1.787;       % [mM] 
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ks = 25;                 % [1/ms]       
koCa = 10;               % [mM^-2 1/ms]   %default 10   modified 20 
kom = 0.06;              % [1/ms]      
kiCa = 0.5;              % [1/mM/ms] 
kim = 0.005;             % [1/ms] 
ec50SR = 0.45;           % [mM] 
 
% Buffering parameters 
% Note: we are using [1/ms] and [1/mM/ms], which differs from that in the paper  
% koff: [1/s] = 1e-3*[1/ms];  kon: [1/uM/s] = [1/mM/ms] 
Bmax_Naj = 7.561;       % [mM]  % Na buffering 
Bmax_Nasl = 1.65;       % [mM] 
koff_na = 1e-3;         % [1/ms] 
kon_na = 0.1e-3;        % [1/mM/ms] 
Bmax_TnClow = 70e-3;    % [mM]                      % TnC low affinity 
koff_tncl = 19.6e-3;    % [1/ms]  
kon_tncl = 32.7;        % [1/mM/ms] 
Bmax_TnChigh = 140e-3;  % [mM]                      % TnC high affinity  
koff_tnchca = 0.032e-3; % [1/ms]  
kon_tnchca = 2.37;      % [1/mM/ms] 
koff_tnchmg = 3.33e-3;  % [1/ms]  
kon_tnchmg = 3e-3;      % [1/mM/ms] 
Bmax_CaM = 24e-3;       % [mM]  % CaM buffering 
koff_cam = 238e-3;      % [1/ms]  
kon_cam = 34;           % [1/mM/ms] 
Bmax_myosin = 140e-3;   % [mM]                      % Myosin buffering 
koff_myoca = 0.46e-3;   % [1/ms] 
kon_myoca = 13.8;       % [1/mM/ms] 
koff_myomg = 0.057e-3;  % [1/ms] 
kon_myomg = 0.0157;     % [1/mM/ms] 
Bmax_SR = 19*.9e-3;     % [mM] (Bers text says 47e-3) 19e-3 
koff_sr = 60e-3;        % [1/ms] 
kon_sr = 100;           % [1/mM/ms] 
Bmax_SLlowsl = 37.4e-3*Vmyo/Vsl;        % [mM]    % SL buffering 
Bmax_SLlowj = 4.6e-3*Vmyo/Vjunc*0.1;    % [mM]     
koff_sll = 1300e-3;     % [1/ms] 
kon_sll = 100;          % [1/mM/ms] 
Bmax_SLhighsl = 13.4e-3*Vmyo/Vsl;       % [mM]  
Bmax_SLhighj = 1.65e-3*Vmyo/Vjunc*0.1;  % [mM]  
koff_slh = 30e-3;       % [1/ms] 
kon_slh = 100;          % [1/mM/ms] 
Bmax_Csqn = 140e-3*Vmyo/Vsr;            % [mM] % Bmax_Csqn = 2.6;      % Csqn buffering 
koff_csqn = 65;         % [1/ms]  
kon_csqn = 100;         % [1/mM/ms]  
 
 
%% Membrane Currents 
% I_Na: Fast Na Current 
am = 0.32*(y(39)+47.13)/(1-exp(-0.1*(y(39)+47.13))); 
bm = 0.08*exp(-y(39)/11); 
if y(39) >= -40 
    ah = 0; aj = 0; 
    bh = 1/(0.13*(1+exp(-(y(39)+10.66)/11.1))); 
    bj = 0.3*exp(-2.535e-7*y(39))/(1+exp(-0.1*(y(39)+32))); 
else 
    ah = 0.135*exp((80+y(39))/-6.8); 
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    bh = 3.56*exp(0.079*y(39))+3.1e5*exp(0.35*y(39)); 
    aj = (-1.2714e5*exp(0.2444*y(39))-3.474e-5*exp(-
0.04391*y(39)))*(y(39)+37.78)/(1+exp(0.311*(y(39)+79.23))); 
    bj = 0.1212*exp(-0.01052*y(39))/(1+exp(-0.1378*(y(39)+40.14))); 
end 
ydot(1) = am*(1-y(1))-bm*y(1); 
ydot(2) = ah*(1-y(2))-bh*y(2); 
ydot(3) = aj*(1-y(3))-bj*y(3); 
 
 
I_Na_junc = Fjunc*GNa*y(1)^3*y(2)*y(3)*(y(39)-ena_junc); 
I_Na_sl = Fsl*GNa*y(1)^3*y(2)*y(3)*(y(39)-ena_sl); 
 
% I_Na_junc= I_Na_junc1*(1-flag)+I_Na_junc2*flag; 
% I_Na_sl= I_Na_sl1*(1-flag)+I_Na_sl2*flag; 
I_Na = I_Na_junc+I_Na_sl; 
 
 
 
% I_nabk: Na Background Current 
I_nabk_junc = Fjunc*GNaB*(y(39)-ena_junc); 
I_nabk_sl = Fsl*GNaB*(y(39)-ena_sl); 
I_nabk = I_nabk_junc+I_nabk_sl; 
 
% I_nak: Na/K Pump Current 
sigma = (exp(Nao/67.3)-1)/7; 
fnak = 1/(1+0.1245*exp(-0.1*y(39)*FoRT)+0.0365*sigma*exp(-y(39)*FoRT)); 
I_nak_junc = Fjunc*IbarNaK*fnak*Ko /(1+(KmNaip/y(32))^4) /(Ko+KmKo); 
I_nak_sl = Fsl*IbarNaK*Q10NaK*fnak*Ko /(1+(KmNaip/y(33))^4) /(Ko+KmKo); 
I_nak = I_nak_junc+I_nak_sl; 
 
% I_kr: Rapidly Activating K Current 
gkr = 0.03*sqrt(Ko/5.4); 
xrss = 1/(1+exp(-(y(39)+50)/7.5)); 
tauxr = 1/(1.38e-3*(y(39)+7)/(1-exp(-0.123*(y(39)+7)))+6.1e-4*(y(39)+10)/(exp(0.145*(y(39)+10))-1)); 
ydot(12) = (xrss-y(12))/tauxr; 
rkr = 1/(1+exp((y(39)+33)/22.4)); 
I_kr = gkr*y(12)*rkr*(y(39)-ek); 
 
% I_ks: Slowly Activating K Current 
pcaks_junc = -log10(y(36))+3.0;  
pcaks_sl = -log10(y(37))+3.0;   
gks_junc = 0.4*(0.057 +0.19/(1+ exp((-7.2+pcaks_junc)/0.6))); 
gks_sl = 0.4*(0.057 +0.19/(1+ exp((-7.2+pcaks_sl)/0.6)));  
% gks_junc = 0.07*(0.057 +0.19/(1+ exp((-7.2+pcaks_junc)/0.6))); 
% gks_sl = 0.07*(0.057 +0.19/(1+ exp((-7.2+pcaks_sl)/0.6)));  
eks = (1/FoRT)*log((Ko+pNaK*Nao)/(y(35)+pNaK*y(34)));  
xsss = 1/(1+exp(-(y(39)+40)/16.7)); 
tauxs = 1/(7.19e-5*(y(39)+30)/(1-exp(-0.148*(y(39)+30)))+1.31e-4*(y(39)+30)/(exp(0.0687*(y(39)+30))-
1));  
ydot(13) = (xsss-y(13))/tauxs; 
I_ks_junc = Fjunc*gks_junc*y(13)^2*(y(39)-eks); 
I_ks_sl = Fsl*gks_sl*y(13)^2*(y(39)-eks); 
I_ks = I_ks_junc+I_ks_sl; 
 
%I_kp: Plateau K current 
 92 
kp_kp = 1/(1+exp((7.488-y(39))/5.98)); %%%%///?? 
I_kp_junc = Fjunc*gkp*kp_kp*(y(39)-ek); 
I_kp_sl = Fsl*gkp*kp_kp*(y(39)-ek); 
I_kp = I_kp_junc+I_kp_sl; 
 
%% I_to: Transient Outward K Current (slow and fast components) 
xtoss = 1/(1+exp(-(y(39)+3.0)/15)); 
ytoss = 1/(1+exp((y(39)+33.5)/10)); 
rtoss = 1/(1+exp((y(39)+33.5)/10)); 
tauxtos = 9/(1+exp((y(39)+3.0)/15))+0.5; 
tauytos = 3e3/(1+exp((y(39)+60.0)/10))+30; 
%tauytos = 182/(1+exp((y(39)+33.5)/10))+1; 
taurtos = 2.8e3/(1+exp((y(39)+60.0)/10))+220; %Fei changed here!! time-dependent gating variable 
%taurtos =8085/(1+exp((y(39)+33.5)/10))+313; 
ydot(8) = (xtoss-y(8))/tauxtos; 
ydot(9) = (ytoss-y(9))/tauytos; 
ydot(40)= (rtoss-y(40))/taurtos; %Fei changed here!! time-dependent gating variable 
I_tos = GtoSlow*y(8)*(y(9)+0.5*y(40))*(y(39)-ek);    % [uA/uF] 
 
tauxtof = 3.5*exp(-y(39)*y(39)/30/30)+1.5; 
%tauxtof = 3.5*exp(-((y(39)+3)/30)^2)+1.5; 
tauytof = 20.0/(1+exp((y(39)+33.5)/10))+20.0; 
%tauytof = 20.0/(1+exp((y(39)+33.5)/10))+20.0; 
ydot(10) = (xtoss-y(10))/tauxtof; 
ydot(11) = (ytoss-y(11))/tauytof; 
I_tof = GtoFast*y(10)*y(11)*(y(39)-ek); 
I_to = I_tos + I_tof; 
 
% I_ki: Time-Independent K Current 
aki = 1.02/(1+exp(0.2385*(y(39)-ek-59.215))); 
bki =(0.49124*exp(0.08032*(y(39)+5.476-ek)) + exp(0.06175*(y(39)-ek-594.31))) /(1 + exp(-
0.5143*(y(39)-ek+4.753))); 
kiss = aki/(aki+bki); 
I_ki = 0.9*sqrt(Ko/5.4)*kiss*(y(39)-ek); 
 
% I_ClCa: Ca-activated Cl Current, I_Clbk: background Cl Current 
I_ClCa_junc = Fjunc*GClCa/(1+KdClCa/y(36))*(y(39)-ecl); 
I_ClCa_sl = Fsl*GClCa/(1+KdClCa/y(37))*(y(39)-ecl); 
I_ClCa = I_ClCa_junc+I_ClCa_sl; 
I_Clbk = GClB*(y(39)-ecl); 
 
%% I_Ca: L-type Calcium Current 
dss = 1/(1+exp(-(y(39)+23.5)/6.0)); 
taud = dss*(1-exp(-(y(39)+22.5)/6.0))/(0.035*(y(39)+22.5)); 
fss = 1/(1+exp((y(39)+35.06)/3.6))+0.6/(1+exp((50-y(39))/20)); 
tauf = 1/(0.0197*exp( -(0.0337*(y(39)+14.5))^2 )+0.02); 
ydot(4) = (dss-y(4))/taud; 
ydot(5) = (fss-y(5))/tauf; 
ydot(6) = 1.7*y(36)*(1-y(6))-11.9e-3*y(6); % fCa_junc   koff!!!!!!!! 
ydot(7) = 1.7*y(37)*(1-y(7))-11.9e-3*y(7); % fCa_sl 
fcaCaMSL= 0.1/(1+(0.01/y(37))); 
fcaCaj= 0.1/(1+(0.01/y(36))); 
fcaCaMSL=0; 
fcaCaj= 0; 
%y(6)=0; 
%y(7)=0; 
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ibarca_j = pCa*4*(y(39)*Frdy*FoRT) * (0.341*y(36)*exp(2*y(39)*FoRT)-0.341*Cao) 
/(exp(2*y(39)*FoRT)-1); 
ibarca_sl = pCa*4*(y(39)*Frdy*FoRT) * (0.341*y(37)*exp(2*y(39)*FoRT)-0.341*Cao) 
/(exp(2*y(39)*FoRT)-1); 
ibark = pK*(y(39)*Frdy*FoRT)*(0.75*y(35)*exp(y(39)*FoRT)-0.75*Ko) /(exp(y(39)*FoRT)-1); 
ibarna_j = pNa*(y(39)*Frdy*FoRT) *(0.75*y(32)*exp(y(39)*FoRT)-0.75*Nao)  /(exp(y(39)*FoRT)-1); 
ibarna_sl = pNa*(y(39)*Frdy*FoRT) *(0.75*y(33)*exp(y(39)*FoRT)-0.75*Nao)  /(exp(y(39)*FoRT)-1); 
I_Ca_junc = (Fjunc_CaL*ibarca_j*y(4)*y(5)*((1-y(6))+fcaCaj)*Q10CaL^Qpow)*0.45*1; 
I_Ca_sl = (Fsl_CaL*ibarca_sl*y(4)*y(5)*((1-y(7))+fcaCaMSL)*Q10CaL^Qpow)*0.45*1; 
I_Ca = I_Ca_junc+I_Ca_sl; 
I_CaK = (ibark*y(4)*y(5)*(Fjunc_CaL*(fcaCaj+(1-y(6)))+Fsl_CaL*(fcaCaMSL+(1-
y(7))))*Q10CaL^Qpow)*0.45*1; 
I_CaNa_junc = (Fjunc_CaL*ibarna_j*y(4)*y(5)*((1-y(6))+fcaCaj)*Q10CaL^Qpow)*0.45*1; 
I_CaNa_sl = (Fsl_CaL*ibarna_sl*y(4)*y(5)*((1-y(7))+fcaCaMSL)*Q10CaL^Qpow)*.45*1; 
I_CaNa = I_CaNa_junc+I_CaNa_sl; 
I_Catot = I_Ca+I_CaK+I_CaNa; 
 
% I_ncx: Na/Ca Exchanger flux 
Ka_junc = 1/(1+(Kdact/y(36))^3); 
Ka_sl = 1/(1+(Kdact/y(37))^3); 
s1_junc = exp(nu*y(39)*FoRT)*y(32)^3*Cao; 
s1_sl = exp(nu*y(39)*FoRT)*y(33)^3*Cao; 
s2_junc = exp((nu-1)*y(39)*FoRT)*Nao^3*y(36); 
s3_junc = KmCai*Nao^3*(1+(y(32)/KmNai)^3) + 
KmNao^3*y(36)*(1+y(36)/KmCai)+KmCao*y(32)^3+y(32)^3*Cao+Nao^3*y(36); 
s2_sl = exp((nu-1)*y(39)*FoRT)*Nao^3*y(37); 
s3_sl = KmCai*Nao^3*(1+(y(33)/KmNai)^3) + 
KmNao^3*y(37)*(1+y(37)/KmCai)+KmCao*y(33)^3+y(33)^3*Cao+Nao^3*y(37); 
I_ncx_junc = Fjunc*IbarNCX*Q10NCX^Qpow*Ka_junc*(s1_junc-s2_junc)/s3_junc/(1+ksat*exp((nu-
1)*y(39)*FoRT)); 
I_ncx_sl = Fsl*IbarNCX*Q10NCX^Qpow*Ka_sl*(s1_sl-s2_sl)/s3_sl/(1+ksat*exp((nu-1)*y(39)*FoRT)); 
I_ncx = I_ncx_junc+I_ncx_sl; 
 
% I_pca: Sarcolemmal Ca Pump Current 
I_pca_junc = Fjunc*Q10SLCaP^Qpow*IbarSLCaP*y(36)^1.6/(KmPCa^1.6+y(36)^1.6); 
I_pca_sl = Fsl*Q10SLCaP^Qpow*IbarSLCaP*y(37)^1.6/(KmPCa^1.6+y(37)^1.6); 
I_pca = I_pca_junc+I_pca_sl; 
 
% I_cabk: Ca Background Current 
I_cabk_junc = Fjunc*GCaB*(y(39)-eca_junc); 
I_cabk_sl = Fsl*GCaB*(y(39)-eca_sl); 
I_cabk = I_cabk_junc+I_cabk_sl; 
 
%% SR fluxes: Calcium Release, SR Ca pump, SR Ca leak 
MaxSR = 15; MinSR = 1; 
kCaSR = MaxSR - (MaxSR-MinSR)/(1+(ec50SR/y(31))^2.5); 
koSRCa = koCa/kCaSR; 
kiSRCa = kiCa*kCaSR; 
RI = 1-y(14)-y(15)-y(16); 
ydot(14) = (kim*RI-kiSRCa*y(36)*y(14))-(koSRCa*y(36)^2*y(14)-kom*y(15));   % R 
ydot(15) = (koSRCa*y(36)^2*y(14)-kom*y(15))-(kiSRCa*y(36)*y(15)-kim*y(16));% O 
ydot(16) = (kiSRCa*y(36)*y(15)-kim*y(16))-(kom*y(16)-koSRCa*y(36)^2*RI);   % I 
J_SRCarel = ks*y(15)*(y(31)-y(36));          % [mM/ms] 
 
J_serca = Q10SRCaP^Qpow*Vmax_SRCaP*((y(38)/Kmf)^hillSRCaP-(y(31)/Kmr)^hillSRCaP)... 
    /(1+(y(38)/Kmf)^hillSRCaP+(y(31)/Kmr)^hillSRCaP); 
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J_SRleak = 5.348e-6*(y(31)-y(36));           %   [mM/ms] 
 
%% Sodium and Calcium Buffering 
ydot(17) = kon_na*y(32)*(Bmax_Naj-y(17))-koff_na*y(17);        % NaBj      [mM/ms] 
ydot(18) = kon_na*y(33)*(Bmax_Nasl-y(18))-koff_na*y(18);       % NaBsl     [mM/ms] 
 
% Cytosolic Ca Buffers 
% ydot(19) = nc*(ydot(41)+ydot(42)+ydot(43)); 
ydot(19) = kon_tncl*y(38)*(Bmax_TnClow-y(19))-koff_tncl*y(19);            % TnCL      [mM/ms] 
ydot(20) = kon_tnchca*y(38)*(Bmax_TnChigh-y(20)-y(21))-koff_tnchca*y(20); % TnCHc     [mM/ms] 
ydot(21) = kon_tnchmg*Mgi*(Bmax_TnChigh-y(20)-y(21))-koff_tnchmg*y(21);   % TnCHm     [mM/ms] 
ydot(22) = kon_cam*y(38)*(Bmax_CaM-y(22))-koff_cam*y(22);                 % CaM       [mM/ms] 
ydot(23) = kon_myoca*y(38)*(Bmax_myosin-y(23)-y(24))-koff_myoca*y(23);    % Myosin_ca [mM/ms] 
ydot(24) = kon_myomg*Mgi*(Bmax_myosin-y(23)-y(24))-koff_myomg*y(24);      % Myosin_mg 
[mM/ms] 
ydot(25) = kon_sr*y(38)*(Bmax_SR-y(25))-koff_sr*y(25);                    % SRB       [mM/ms] 
J_CaB_cytosol = sum(ydot(19:25)); 
 
% Junctional and SL Ca Buffers 
ydot(26) = kon_sll*y(36)*(Bmax_SLlowj-y(26))-koff_sll*y(26);       % SLLj      [mM/ms] 
ydot(27) = kon_sll*y(37)*(Bmax_SLlowsl-y(27))-koff_sll*y(27);      % SLLsl     [mM/ms] 
ydot(28) = kon_slh*y(36)*(Bmax_SLhighj-y(28))-koff_slh*y(28);      % SLHj      [mM/ms] 
ydot(29) = kon_slh*y(37)*(Bmax_SLhighsl-y(29))-koff_slh*y(29);     % SLHsl     [mM/ms] 
J_CaB_junction = ydot(26)+ydot(28); 
J_CaB_sl = ydot(27)+ydot(29); 
 
%% Ion concentrations 
% SR Ca Concentrations 
ydot(30) = kon_csqn*y(31)*(Bmax_Csqn-y(30))-koff_csqn*y(30);       % Csqn      [mM/ms] 
ydot(31) = J_serca-(J_SRleak*Vmyo/Vsr+J_SRCarel)-ydot(30);         % Ca_sr     [mM/ms] %Ratio 3 leak 
current 
 
% Sodium Concentrations 
I_Na_tot_junc = I_Na_junc+I_nabk_junc+3*I_ncx_junc+3*I_nak_junc+I_CaNa_junc;   % [uA/uF] 
I_Na_tot_sl = I_Na_sl+I_nabk_sl+3*I_ncx_sl+3*I_nak_sl+I_CaNa_sl;   % [uA/uF] 
 
ydot(32) = -I_Na_tot_junc*Cmem/(Vjunc*Frdy)+J_na_juncsl/Vjunc*(y(33)-y(32))-ydot(17); 
ydot(33) = -I_Na_tot_sl*Cmem/(Vsl*Frdy)+J_na_juncsl/Vsl*(y(32)-y(33))... 
   +J_na_slmyo/Vsl*(y(34)-y(33))-ydot(18); 
%ydot(32) = 0; 
%ydot(33) = 0; 
ydot(34) = J_na_slmyo/Vmyo*(y(33)-y(34));             % [mM/msec]  
%ydot(34)=0; 
 
% Potassium Concentration 
I_K_tot = I_to+I_kr+I_ks+I_ki-2*I_nak+I_CaK+I_kp;     % [uA/uF] 
% ydot(35) = 0; %-I_K_tot*Cmem/(Vmyo*Frdy);           % [mM/msec] 
ydot(35) =0; % -I_K_tot*Cmem/(Vmyo*Frdy); 
 
% Calcium Concentrations 
I_Ca_tot_junc = I_Ca_junc+I_cabk_junc+I_pca_junc-2*I_ncx_junc;                   % [uA/uF] 
I_Ca_tot_sl = I_Ca_sl+I_cabk_sl+I_pca_sl-2*I_ncx_sl;            % [uA/uF] 
ydot(36) = -I_Ca_tot_junc*Cmem/(Vjunc*2*Frdy)+J_ca_juncsl/Vjunc*(y(37)-y(36))... 
    -J_CaB_junction+(J_SRCarel)*Vsr/Vjunc+J_SRleak*Vmyo/Vjunc;  % Ca_j 
ydot(37) = -I_Ca_tot_sl*Cmem/(Vsl*2*Frdy)+J_ca_juncsl/Vsl*(y(36)-y(37))... 
    + J_ca_slmyo/Vsl*(y(38)-y(37))-J_CaB_sl;   % Ca_sl 
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% ydot(38) = -J_serca*Vsr/Vmyo-J_CaB_cytosol;%+J_ca_slmyo/Vmyo*(y(37)-y(38));    % [mM/msec] 
ydot(38) = -J_serca*Vsr/Vmyo-J_CaB_cytosol +J_ca_slmyo/Vmyo*(y(37)-y(38)); 
%% Membrane Potential 
I_Na_tot = I_Na_tot_junc + I_Na_tot_sl;          % [uA/uF] 
I_Cl_tot = I_ClCa+I_Clbk;                        % [uA/uF] 
I_Ca_tot = I_Ca_tot_junc+I_Ca_tot_sl; 
I_tot = I_Na_tot+I_Cl_tot+I_Ca_tot+I_K_tot; 
if(mod(t,2000)<1) 
    I_app =-40; 
else 
    I_app =0; 
end 
ydot(39) = -(I_tot+I_app); 
vmax = ydot(39); 
end 
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APPENDIX E 
C++ CODE FOR MAHAJAN MODEL 
CELL.CPP 
 
#ifndef ___CELL 
#define ___CELL 
#include "cell.h" 
 
 
CCell::CCell(void) : y(new double[N]), 
 xm(y[0]), xh(y[1]), xj(y[2]), xr(y[3]),  
 xs1(y[4]), xs2(y[5]), xtos(y[6]), ytos(y[7]), 
 v(y[8]), cp(y[9]), cs(y[10]), ci(y[11]),  
 cj(y[12]), cjp(y[13]), xir(y[14]), c1(y[15]),  
 c2(y[16]), xi1ca(y[17]), xi1ba(y[18]), xi2ca(y[19]),  
 xi2ba(y[20]), xnai(y[21]), xtof(y[22]), ytof(y[23]),  
 tropi(y[24]), trops(y[25]) 
{ 
// initial conditions 
 xm=0.001145222753;// sodium m-gate 
 xh=0.9898351676;// sodium h-gate 
 xj=0.9930817518;// soiumj-gate 
 
 xr=0.008709989976;// ikr gate variable  
 xs1=0.08433669901;// iks gate variable 
 xs2=0.1412866149;// iks gate varaible  
 
 xtos=0.003757746357;// ito slow activation 
 ytos=0.1553336368;// ito slow inactivation 
 
 v=-86.79545769; // voltage 
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 cp=1.682601371;// averaged dyadic space con. 
 cs=0.3205609256;// averaged submembrane conc. 
 ci=0.3863687451;// myoplasm conc. 
 
 cj=107.0388739;// NSR load 
 cjp=95.76256179;// average JSR load 
 
 xir=0.006462569526;// SR current flux 
 
 // Markov gate variables  
 
 c1=1.925580885e-05;// C1 
 c2=0.9535940241;// C2 
 xi1ca=0.007052299702;// I1_Ca 
 xi1ba=3.629261123e-05;// I1_Ba 
 xi2ca=0.02316349806;// I2_Ca 
 xi2ba=0.01613268649;// I2_Ba 
 
 xnai=14.01807252;// internal Na conc. 
 
 xtof=0.003737842131;// ito fast activation 
 ytof=0.9823715315;// ito slow inactivation 
 
 tropi=29.64807803;// time dependent buffers in myplasm (troponin) 
 trops=26.37726416;// time dependent buffers in submembrane (troponin) 
 
 hpde=0.1; 
 vold = v; 
 jparam=1; 
 
#ifdef ___USE_VAR_FOR_CONST 
 xnao=136.0;//mM   external Na 
 xki=140.0;// mM  internal K 
 xko=5.40;//mM  external K 
 cao=1.8;// mM  external Ca 
 
 gca=182;// ica conductance 
 gtos=0.04;// ito slow conductance  
 gtof=0.11;// ito fast conductance  
 gnaca=0.84;// exchanger strength  
 gkr=0.0125;// Ikr conductance  
 gks=0.32; 
 gkix=0.3;// Ik1 conductance 
 gnak=1.5; 
 vup=0.4;//0.3;// uptake strength 
 taus=4.0;// diffusional delay (ms) 
 gna=12.0;// sodium conductance (mS/micro F)  
 taur=30.0;// spark lifetime (ms) 
 taua=100.0;// NSR-JSR diffusional delay (ms) 
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 av=11.3; 
 cstar=90.0; 
#endif 
} 
CCell::~CCell() 
{ 
 delete[] y; 
} 
void CCell::Prepare(double BCL, int Iter) 
{ 
 if (Iter==0) 
 { 
  double dciold=0; 
  double dciold2=0; 
  bool first=false; 
  int Tn=BCL*10000/hpde, BCLn=BCL/hpde, Durn=stimduration/hpde; 
  for (int tn=0;tn<Tn;tn++) 
  { 
   double t=tn*hpde; 
   if (tn%BCLn < Durn) 
   { 
    if (first) 
    { 
     if (fabs(ci-dciold2)<0.00001 && t>BCL*300) 
     { 
      break; 
     } 
     dciold2=dciold; 
     dciold=ci; 
     first=false; 
    } 
    Pace(stim); 
   } 
   else 
   { 
    first=true; 
    Pace(); 
   } 
  } 
 } 
 else 
 { 
  int Tn=BCL*Iter/hpde, BCLn=BCL/hpde, Durn=stimduration/hpde; 
  for (int tn=0;tn<Tn;tn++) 
  { 
   if (tn%BCLn < Durn) 
    Pace(stim); 
   else 
    Pace(); 
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  } 
 } 
} 
CCell& CCell::operator=(const CCell& cell) 
{ 
 if (&cell!=this) 
 { 
  for (int i=0;i<N;i++) 
  { 
   y[i]=cell.y[i]; 
  } 
  jparam=cell.jparam; 
  vold=cell.vold; 
  hpde=cell.hpde; 
 #ifdef ___USE_VAR_FOR_CONST 
  xnao=cell.xnao; 
  xki=cell.xki; 
  xko=cell.xko; 
  cao=cell.cao; 
 
  gca=cell.gca; 
  gtos=cell.gtos; 
  gtof=cell.gtof; 
  gnaca=cell.gnaca; 
  gkr=cell.gkr; 
  gks=cell.gks; 
  gkix=cell.gkix; 
  gnak=cell.gnak; 
  vup=cell.vup; 
  taus=cell.taus; 
  gna=cell.gna; 
  taur=cell.taur; 
  taua=cell.taua; 
  av=cell.av; 
  cstar=cell.cstar; 
 #endif 
 } 
 return(*this); 
} 
void CCell::ClampAP(double t, double T, double APD) 
{ 
 const double Vmin=-80;//-80mV 
 const double Vmax=30;//30mV 
 double clampv; 
 if (APD==0) 
 { 
  const double a=2.0/3.0*1000; 
  double x=a/(a+T); 
  int m=(int)(t/T); 
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  if (m*T+x*T>t) 
  { 
   clampv=Vmin+(Vmax-Vmin)*sqrt(1-((t-m*T)/x/T)*((t-m*T)/x/T)); 
  } 
  else 
  { 
   clampv=Vmin; 
  } 
 } 
 else 
 { 
  double x=APD/T; 
  int m=(int)(t/T); 
  if (m*T+x*T>t) 
  { 
   clampv=Vmin+(Vmax-Vmin)*sqrt(1-((t-m*T)/x/T)*((t-m*T)/x/T)); 
  } 
  else 
  { 
   clampv=Vmin; 
  } 
 } 
 
 double dv=(vold-v)/hpde; 
 vold=v; 
 double Itotal; 
 if(fabs(dv)>25.0)// then finer time step when dv/dt large 
 { 
  hode=hpde/10; 
  for (int iii=0;iii<10;iii++) 
  { 
   v=clampv; 
   Itotal=PaceX(0); 
  } 
 } 
 else 
 { 
  hode=hpde; 
  v=clampv; 
  Itotal=PaceX(0); 
 } 
} 
double CCell::Pace(double Istim) 
{ 
// -------------time step adjustment ------------------------ 
 double dv=(vold-v)/hpde; 
 vold=v; 
 double Itotal; 
 if(fabs(dv)>25.0)// then finer time step when dv/dt large 
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 { 
  hode=hpde/10; 
  for (int iii=0;iii<10;iii++) 
  { 
   Itotal=PaceX(Istim); 
  } 
 } 
 else 
 { 
  hode=hpde; 
  Itotal=PaceX(Istim); 
 } 
 return Itotal; 
} 
double CCell::PaceVClamp(double clampv) 
{ 
// -------------time step adjustment ------------------------ 
 double dv=(vold-v)/hpde; 
 vold=v; 
 double Itotal; 
 if(fabs(dv)>25.0)// then finer time step when dv/dt large 
 { 
  hode=hpde/10; 
  for (int iii=0;iii<10;iii++) 
  { 
   v=clampv; 
   Itotal=PaceX(0); 
  } 
 } 
 else 
 { 
  hode=hpde; 
  v=clampv; 
  Itotal=PaceX(0); 
 } 
 return Itotal; 
} 
 
double CCell::PaceX(double Istim) 
{ 
 double xik1=comp_ik1(); 
 double xito=comp_ito();//itos and itof 
 double xinak=comp_inak(); 
 double csm=cs/1000.0;// convert micro M to mM 
 double xinacaq=comp_inaca(csm); 
//----------- Equations for Ca cycling ------------------------- 
 double xdif=(cs-ci)/taus;//diffusion from submembrane to myoplasm 
 // Troponin kinetics 
 const double xkon=0.0327; 
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 const double xkoff=0.0196; 
 const double btrop=70.0; 
 double xbi=xkon*ci*(btrop-tropi)-xkoff*tropi; 
 double xbs=xkon*cs*(btrop-trops)-xkoff*trops; 
 
 double xiup=comp_iup(); 
 double xileak=comp_ileak(); 
 
 double po=comp_icalpo(); 
 double rxa=comp_rxa(csm); 
 double xicaq=gca*po*rxa;// Ca current in micro M/ms 
 
 double dcs=comp_inst_buffer(cs)*(50.0*(xir-xdif-xicaq+xinacaq)-xbs); 
 double dci=comp_inst_buffer(ci)*(xdif-xiup+xileak-xbi); 
 double dcj=-xir+xiup-xileak;// SR load dynamics  
 double dcjp=(cj-cjp)/taua;// NSR-JSR relaxation dynamics  
 double Qr=comp_Q(); 
 double dir=comp_dir(po, Qr, rxa, dcj); 
 double dcp=comp_dcp(po, Qr, rxa); 
 
 double xina=comp_ina(); 
 double xikr=comp_ikr(); 
 double xiks=comp_iks(); 
 
 cp+=dcp*hode; 
 cs+=dcs*hode; 
 ci+=dci*hode; 
 cj+=dcj*hode; 
 xir+=dir*hode; 
 cjp+=dcjp*hode; 
 
 tropi+=xbi*hode; 
 trops+=xbs*hode; 
 
//-------convert ion flow to current--------- 
 const double wca=8.0;//conversion factor between micro molar/ms to micro amps/ micro farads 
 double xinaca=wca*xinacaq; 
 double xica=2.0*wca*xicaq; 
//--------sodium dynamics ------------------------- 
 const double xrr=(1.0/wca)/1000.0;// note: sodium is in m molar so need to divide by 1000 
 xnai+=(-xrr*(xina+3.0*xinak+3.0*xinaca))*hode; 
// -------- dV/dt ------------------------------------ 
 double Itotal=(-(xina+xik1+xikr+xiks+xito+xinaca+xica+xinak)+ Istim); 
 v+=Itotal*hode; 
 #ifdef ___REC_CURRENTS 
 _inaca=xinaca;_ica=xica;_iks=xiks;_ikr=xikr;_ik1=xik1;_ina=xina;_inak=xinak;_iup=xiup; 
 #endif 
 return Itotal; 
} 
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//----------- sodium current following Hund-Rudy ------------------- 
double CCell::comp_ina(void) 
{ 
 double ena = (1.0/frt)*log(xnao/xnai); 
 double am; 
 if (fabs(v+47.13)<0.001/0.1) 
  am=3.2; 
 else 
  am = 0.32*(v+47.13)/(1.0-exp(-0.1*(v+47.13))); 
 double bm = 0.08*exp(-v/11.0); 
 double ah,bh,aj,bj; 
 if(v<(-40.0)) 
 { 
   ah=0.135*exp((80.0+v)/(-6.8)); 
   bh=3.56*exp(0.079*v)+310000.0*exp(0.35*v); 
   aj=((-127140.0*exp(0.2444*v)-0.00003474*exp(-
0.04391*v))*(v+37.78))/(1.0+exp(0.311*(v+79.23))); 
   bj=(0.1212*exp(-0.01052*v))/(1.0+exp(-0.1378*(v+40.14))); 
 } 
 else 
 { 
   ah=0.0; 
   bh=1.0/(0.13*(1.0+exp((v+10.66)/(-11.1)))); 
   aj=0.0; 
   bj=(0.3*exp(-0.0000002535*v))/(1.0+exp(-0.1*(v+32.0))); 
 } 
  
 double tauh=1.0/(ah+bh); 
 double tauj=1.0/(aj+bj)*jparam; 
 double taum=1.0/(am+bm); 
 double xina= gna*xh*xj*xm*xm*xm*(v-ena); 
 
 xh = ah/(ah+bh)-((ah/(ah+bh))-xh)*exp(-hode/tauh); 
 xj = aj/(aj+bj)-((aj/(aj+bj))-xj)*exp(-hode/tauj); 
 xm = am/(am+bm)-((am/(am+bm))-xm)*exp(-hode/taum); 
 return xina; 
} 
//-------------- Ikr following Shannon------------------  
double CCell::comp_ikr(void) 
{ 
 #ifdef ___USE_VAR_FOR_CONST 
 double ek = (1.0/frt)*log(xko/xki);// K reversal potential 
 #endif 
 const double gss=sqrt(xko/5.4); 
 double xkrv1; 
 if (fabs(v+7.0)<0.001/0.123) 
  xkrv1=0.00138/0.123; 
 else 
  xkrv1=0.00138*(v+7.0)/( 1.-exp(-0.123*(v+7.0))); 
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 double xkrv2; 
 if (fabs(v+10.0)<0.001/0.145) 
  xkrv2=0.00061/0.145; 
 else 
  xkrv2=0.00061*(v+10.0)/(exp( 0.145*(v+10.0))-1.0); 
 double taukr=1.0/(xkrv1+xkrv2); 
 double xkrinf=1.0/(1.0+exp(-(v+50.0)/7.5)); 
 double rg=1.0/(1.0+exp((v+33.0)/22.4)); 
 double xikr=gkr*gss*xr*rg*(v-ek); 
 xr=xkrinf-(xkrinf-xr)*exp(-hode/taukr); 
 return xikr; 
} 
// ----- Iks modified from Shannon, with new Ca dependence------------ 
double CCell::comp_iks(void) 
{ 
 const double prnak=0.018330; 
 double eks=(1.0/frt)*log((xko+prnak*xnao)/(xki+prnak*xnai)); 
 double xs1ss=1.0/(1.0+exp(-(v-1.50)/16.70)); 
 double xs2ss=xs1ss; 
 double tauxs1; 
 if (fabs(v+30.0)<0.001/0.0687) 
  tauxs1=1/(0.0000719/0.148+0.000131/0.0687); 
 else 
  tauxs1=1.0/(0.0000719*(v+30.0)/(1.0-exp(-
0.148*(v+30.0)))+0.000131*(v+30.0)/(exp(0.0687*(v+30.0))-1.0)); 
 double tauxs2=4*tauxs1; 
 double gksx=0.433*(1+0.8/(1+pow((0.5/ci),3))); 
 double xiks=gks*gksx*xs1*xs2*(v-eks); 
 xs1=xs1ss-(xs1ss-xs1)*exp(double(-hode/tauxs1)); 
 xs2=xs2ss-(xs2ss-xs2)*exp(double(-hode/tauxs2)); 
 return xiks; 
} 
//------Ik1 following Luo-Rudy formulation (from Shannon model) ------ 
double CCell::comp_ik1(void) 
{ 
 #ifdef ___USE_VAR_FOR_CONST 
 double ek = (1.0/frt)*log(xko/xki);// K reversal potential 
 #endif 
 const double gki=(sqrt(xko/5.4)); 
 double aki=1.02/(1.0+exp(0.2385*(v-ek-59.215))); 
 double bki=(0.49124*exp(0.08032*(v-ek+5.476))+exp(0.061750*(v-ek-594.31)))/(1.0+exp(-0.5143*(v-
ek+4.753))); 
 double xkin=aki/(aki+bki); 
 double xik1=gkix*gki*xkin*(v-ek); 
 return xik1; 
} 
//------- Ito slow following Shannon et. al. 2005 ----------- 
//------- Ito fast following Shannon et. al. 2005 ----------- 
double CCell::comp_ito(void) 
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{ 
 #ifdef ___USE_VAR_FOR_CONST 
 double ek = (1.0/frt)*log(xko/xki);// K reversal potential 
 #endif 
 double rt1=-(v+3.0)/15.0; 
 double rt2=(v+33.5)/10.0; 
 double rt3=(v+60.0)/10.0; 
 double xtos_inf=1.0/(1.0+exp(rt1)); 
 double ytos_inf=1.0/(1.0+exp(rt2)); 
 double rs_inf=1.0/(1.0+exp(rt2)); 
 double txs=9.0/(1.0+exp(-rt1)) + 0.5; 
 double tys=3000.0/(1.0+exp(rt3)) + 30.0; 
 double xitos=gtos*xtos*(ytos+0.5*rs_inf)*(v-ek);// ito slow 
 xtos = xtos_inf-(xtos_inf-xtos)*exp(-hode/txs); 
 ytos = ytos_inf-(ytos_inf-ytos)*exp(-hode/tys); 
 
 double xtof_inf=xtos_inf; 
 double ytof_inf=ytos_inf; 
 double rt4=-(v/30.0)*(v/30.0); 
 double rt5=(v+33.5)/10.0; 
 double txf=3.5*exp(rt4)+1.5; 
 double tyf=20.0/(1.0+exp(rt5))+20.0; 
 double xitof=gtof*xtof*ytof*(v-ek);// ito fast 
 xtof = xtof_inf-(xtof_inf-xtof)*exp(-hode/txf); 
 ytof = ytof_inf-(ytof_inf-ytof)*exp(-hode/tyf); 
 #ifdef ___REC_CURRENTS 
 _itof=xitof;_itos=xitos; 
 #endif 
 return xitos+xitof; 
} 
// -------Inak (sodium-potassium exchanger) following Shannon -------------- 
double CCell::comp_inak(void) 
{ 
 const double xkmko=1.5; //these are Inak constants adjusted to fit 
       //the experimentally measured dynamic restitution 
curve 
 const double xkmnai=12.0; 
 const double sigma = (exp(xnao/67.3)-1.0)/7.0; 
 double fnak = 1.0/(1+0.1245*exp(-0.1*v*frt)+0.0365*sigma*exp(-v*frt)); 
 double xinak = gnak*fnak*(1./(1.+(xkmnai/xnai)))*xko/(xko+xkmko); 
 return xinak; 
} 
// --- Inaca (sodium-calcium exchange) following Shannon and Hund-Rudy------ 
// Note: all concentrations are in mM 
double CCell::comp_inaca(double csm) 
{ 
 double zw3=pow(xnai,3)*cao*exp(v*0.35*frt)-pow(xnao,3)*csm*exp(v*(0.35-1.)*frt); 
 double zw4=1.0+0.2*exp(v*(0.35-1.0)*frt); 
 const double xkdna=0.3;// micro M 
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 double aloss=1.0/(1.0+pow((xkdna/cs),3)); 
 const double xmcao=1.3; 
 const double xmnao=87.5; 
 const double xmnai=12.3; 
 const double xmcai=0.0036; 
 double yz1=xmcao*pow(xnai,3)+pow(xmnao,3)*csm; 
 double yz2=pow(xmnai,3)*cao*(1.0+csm/xmcai); 
 double yz3=xmcai*pow(xnao,3)*(1.0+pow((xnai/xmnai),3)); 
 double yz4=pow(xnai,3)*cao+pow(xnao,3)*csm; 
 double zw8=yz1+yz2+yz3+yz4; 
 double xinacaq=gnaca*aloss*zw3/(zw4*zw8); 
 return xinacaq; 
} 
// compute driving force 
double CCell::comp_rxa(double csm) 
{ 
 const double pca=0.00054; 
 double za=v*2.0*frt; 
 double factor1=4.0*pca*xf*xf/(xxr*temp); 
 double factor=v*factor1; 
 double rxa; 
 if(fabs(za)<0.001) 
 { 
  rxa=factor1*(csm*exp(za)-0.341*(cao))/(2.0*frt); 
 } 
 else 
 { 
  rxa=factor*(csm*exp(za)-0.341*(cao))/(exp(za)-1.0); 
 } 
 return rxa; 
} 
// ------ Markovian Ca current -------------------------------- 
// Markov model:All parameters have been fitted directly to  
// experimental current traces using a multidimensional current fitting 
// routine.  
double CCell::comp_icalpo(void) 
{ 
 const double vth=0.0; 
 const double s6=8.0; 
 
 const double taupo=1.0; 
 double poinf=1.0/(1.0+exp(-(v-vth)/s6)); 
  
 double alpha=poinf/taupo; 
 double beta=(1.0-poinf)/taupo; 
 
 const double r1=0.30; 
 const double r2=3.0; 
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 const double cat=3.0; 
 double fca=1.0/(1.0+pow(double(cat/cp),3)); 
 
 double s1=0.0182688*fca; 
  
 const double s1t=0.00195; 
   
 double xk1=0.024168*fca; 
 const double xk2=1.03615e-4; 
 
 const double xk1t=0.00413; 
 const double xk2t=0.00224; 
 
 double s2=s1*(r1/r2)*(xk2/xk1); 
 const double s2t=s1t*(r1/r2)*(xk2t/xk1t); 
 
 const double vx=-40; 
 const double sx=3.0; 
 double poi=1.0/(1.0+exp(-(v-vx)/sx)); 
 const double tau3=3.0; 
   
 double xk3=(1.0-poi)/tau3; 
 double xk3t=xk3; 
    
 const double vy=-40.0; 
 const double sy=4.0; 
 double prv=1.0-1.0/(1.0+exp(-(v-vy)/sy)); 
 
 double recov=10.0+4954.0*exp(v/15.6); 
 
 const double tca=78.0329; 
 const double cpt=6.09365; 
 double tau_ca=tca/(1.0+pow((cp/cpt),4)); 
 
#ifdef ___FORTHREED 
 double tauca=(recov-tau_ca)*prv+tau_ca+1; 
#else 
 double tauca=(recov-tau_ca)*prv+tau_ca; 
#endif 
 double tauba=(recov-450.0)*prv+450.0; 
 
 const double vyr=-40.0; 
 const double syr=11.32; 
 double poix=1.0/(1.0+exp(-(v-vyr)/syr)); 
 
 double xk6=fca*poix/tauca; 
 double xk5=(1.0-poix)/tauca; 
    
 double xk6t=poix/tauba; 
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 double xk5t=(1.0-poix)/tauba; 
 
 double xk4=xk3*(alpha/beta)*(xk1/xk2)*(xk5/xk6); 
 double xk4t=xk3t*(alpha/beta)*(xk1t/xk2t)*(xk5t/xk6t); 
 
 double po=1.0-xi1ca-xi2ca-xi1ba-xi2ba-c1-c2; 
 
 double dc2= beta*c1+xk5*xi2ca+xk5t*xi2ba-(xk6+xk6t+alpha)*c2; 
 double dc1=alpha*c2+xk2*xi1ca+xk2t*xi1ba+r2*po-(beta+r1+xk1t+xk1)*c1; 
 
 double dxi1ca=xk1*c1+xk4*xi2ca+s1*po-(xk3+xk2+s2)*xi1ca; 
 double dxi2ca=xk3*xi1ca+xk6*c2-(xk5+xk4)*xi2ca; 
 
 double dxi1ba=xk1t*c1+xk4t*xi2ba+s1t*po-(xk3t+xk2t+s2t)*xi1ba; 
 double dxi2ba=xk3t*xi1ba+xk6t*c2-(xk5t+xk4t)*xi2ba; 
 
 c1+=dc1*hode; 
 c2+=dc2*hode; 
 xi1ca+=dxi1ca*hode; 
 xi1ba+=dxi1ba*hode; 
 xi2ca+=dxi2ca*hode; 
 xi2ba+=dxi2ba*hode; 
 return po; 
} 
//----- SERCA2a uptake current ------------------------------------ 
double CCell::comp_iup(void) 
{ 
 const double xup=0.5;// uptake threshold 
 double xiup=vup*ci*ci/(ci*ci + xup*xup); 
 return xiup; 
} 
// ---------leak from the SR-------------------------- 
double CCell::comp_ileak(void) 
{ 
 const double gleak=0.00002069; 
 return gleak*(cj*cj/(cj*cj+50.0*50.0))*(cj*16.667-ci);//vsr/vcell=0.06 
} 
// ---------- buffer dynamics in the myoplasm ----------------------- 
//buffering to calmodulin and SR are instantaneous, while buffering to 
//Troponin C is time dependent.These are important to have reasonable 
//Ca transient.Note: we have buffering in the submembrane space and  
//the myoplasm. 
double CCell::comp_inst_buffer(double c) 
{ 
 const double bcal=24.0; 
 const double xkcal=7.0; 
 const double srmax=47.0; 
 const double srkd=0.6; 
 const double bmem=15.0; 
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 const double kmem=0.3; 
 const double bsar=42.0; 
 const double ksar=13.0; 
 double bpx=bcal*xkcal/((xkcal+c)*(xkcal+c)); 
 double spx=srmax*srkd/((srkd+c)*(srkd+c)); 
 double mempx=bmem*kmem/((kmem+c)*(kmem+c)); 
 double sarpx=bsar*ksar/((ksar+c)*(ksar+c)); 
 return 1.0/(1.0+bpx+spx+mempx+sarpx); 
} 
// --------- release-load functional dependence ---------------- 
double CCell::comp_Q(void) 
{ 
 double bv=(cstar-50.)-av*cstar; 
 double Qr; 
 if (cjp<50) 
 { 
  Qr=0.0; 
 } 
 else if (cjp>50.0 && cjp<cstar) 
 { 
  Qr=cjp-50.0; 
 } 
 else 
 { 
  Qr=av*cjp+bv; 
 } 
 return cj*Qr/cstar; 
} 
double CCell::comp_dir(double po, double Qr, double rxa, double dcj) 
{ 
 const double ay=0.05; 
 double sparkV=exp(-ay*(v+30))/(1.+exp(-ay*(v+30))); 
 const double g=2.58079; 
 double spark_rate=g*po*fabs(rxa)*sparkV; 
 return spark_rate*Qr-xir*(1-taur*dcj/cj)/taur; 
} 
// ----------- dyadic junction dynamics ------------------------ 
double CCell::comp_dcp(double po, double Qr, double rxa) 
{ 
 const double grel=26841.8;// m mol/(cm C)  
 const double ax=0.3576; 
 const double gdyad=9000.0;// m mol/(cm C)  
 double ssr=exp(-ax*(v+30))/(1.0+exp(-ax*(v+30))); 
 double gain=po*Qr*fabs(rxa)*ssr; 
 double xirp=grel*gain; 
 
 double xicap=po*gdyad*fabs(rxa); 
 const double taups=0.5; 
 return xirp+xicap-(cp-cs)/taups; 
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} 
#endif /* ___CELL */ 
 
 
CELL.H 
#ifndef ___CELL_H 
#define ___CELL_H 
 
/* ---------------- UCLA Model ver 1.00 ---------------- ** 
* 
* Contact Information 
* 
* Departments of Medicine (Cardiology) 
* David Geffen School of Medicine at UCLA 
* 
* Daisuke Sato   dasato (at) mednet.ucla.edu 
* Yohannes Shiferaw  yshiferaw (at) csun.edu 
* James N Weiss   JWeiss (at) mednet.ucla.edu 
* 
** ---------------- ------------------- ---------------- */ 
 
 
// #define ___REC_CURRENTS //record currents (more memory) 
// #define ___USE_VAR_FOR_CONST //use variables for Gto Gks Gkr etc. instead of constants (more memory) 
 
#include <iostream> 
using namespace std; 
#define _USE_MATH_DEFINES 
#include <cmath> 
 
class CCell{ 
private: 
 double jparam;//tauj*jparam 
 double PaceX(double stim=0); 
 static const int N=26; 
 static const double Vc; 
 static const double stim; 
 static const double stimduration; 
 static const double temp;// temperature (K) 
 static const double xxr;// 
 static const double xf;// Faraday's constant 
 static const double frt; 
 
 #ifndef ___USE_VAR_FOR_CONST 
 static const double xnao;//mM  external Na 
 static const double xki;// mM  internal K 
 static const double xko;// mM  external K 
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 static const double cao;// mM  external Ca 
 static const double ek; 
 
 static const double gca;// ica conductance 
 static const double gtos;// ito slow conductance  
 static const double gtof;//ito fast conductance  
 static const double gnaca;// exchanger strength  
 static const double gks; 
 static const double gkr; 
 static const double vup;// uptake strength 
 static const double gna;// sodium conductance (mS/micro F)  
 static const double gkix;// Ik1 conductance 
 static const double gnak; 
 
 static const double taur;// spark lifetime (ms) 
 static const double taus;// diffusional delay (ms) 
 static const double taua;// NSR-JSR diffusional delay (ms) 
 static const double av; 
 static const double cstar; 
 #endif 
  
 double comp_ina (void); 
 double comp_ikr(void); 
 double comp_iks(void); 
 double comp_ik1(void); 
 double comp_ito(void); 
 double comp_inak(void); 
 double comp_inaca(double csm); 
 double comp_icalpo(void); 
 double comp_iup(void); 
 double comp_ileak(void); 
 double comp_inst_buffer(double c); 
 
 double comp_rxa(double csm); 
 double comp_Q(void); 
 double comp_dir(double po, double Qr, double rxa, double dcj); 
 double comp_dcp(double po, double Qr, double rxa); 
 double vold; 
 double hode,hpde; 
 
public: 
 double Pace(double stim=0); 
 double PaceVClamp(double clampv); 
 double setJparam(double newjp){jparam=newjp;return newjp;} 
 double setdt(double dtt){hpde=dtt;return hpde;} 
 double getdt(void){return hpde;} 
 int getDim(void){return N;} 
 double getVc(void){return Vc;} 
 double getstim(void){return stim;} 
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 double getstimduration(void){return stimduration;} 
 void ClampAP(double t, double BCL, double APD=0);//BCL ms 
 CCell(void); 
 virtual ~CCell(); 
 CCell& operator=(const CCell& cell); 
 void Prepare(double BCL=300, int Iter=0); 
 double *y; 
 double &xm,&xh,&xj,&xr,&xs1,&xs2,&xtos,&ytos,&v,&ci,&cs,&cj,&cjp,&cp; 
 double &xir,&c1,&c2,&xi1ca,&xi1ba,&xi2ca,&xi2ba,&xnai,&xtof,&ytof,&tropi,&trops; 
 
 #ifdef ___USE_VAR_FOR_CONST 
 double gca;//ica conductance 
 double gtos;// ito slow conductance  
 double gtof;// ito fast conductance  
 double gnaca;// exchanger strength  
 double gks; 
 double gkr; 
 double vup; 
 double gna;// sodium conductance (mS/micro F)  
 double gkix;// Ik1 conductance 
 double gnak; 
 
 double xnao;//mM external Na 
 double xki;//mM internal K 
 double xko;//mM external K 
 double cao;//mM external Ca 
 
 double taus;// diffusional delay (ms) 
 double taur;// spark lifetime (ms) 
 double taua;// NSR-JSR diffusional delay (ms) 
 double av; 
 double cstar; 
 #endif 
 
 #ifdef ___REC_CURRENTS 
 double _inaca,_ica,_iks,_ikr,_itof,_itos,_ik1,_ina,_inak,_iup; 
 #endif 
}; 
 
const double CCell::Vc=-80; 
const double CCell::stim=80; 
const double CCell::stimduration=2; 
 
 
// ---------------constant parameters ------------------------------ 
const double CCell::temp=308.0;// temperature (K) 
const double CCell::xxr=8.314;// 
const double CCell::xf=96.485;// Faraday's constant 
const double CCell::frt=xf/(xxr*temp); 
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#ifndef ___USE_VAR_FOR_CONST 
const double CCell::xnao=136.0;//mM   external Na 
const double CCell::xki=140.0;// mM  internal K 
const double CCell::xko=5.40;//mM  external K 
const double CCell::cao=1.8;// mM  external Ca 
const double CCell::ek = (1.0/frt)*log(xko/xki);// K reversal potential 
 
const double CCell::gca=182;// ica conductance 
const double CCell::gtos=0.04;// ito slow conductance  
const double CCell::gtof=0.11;// ito fast conductance  
const double CCell::gnaca=0.84;// exchanger strength  
const double CCell::gkr=0.0125;// Ikr conductance  
const double CCell::gks=0.32; 
const double CCell::gkix=0.3;// Ik1 conductance 
const double CCell::gnak=1.5; 
const double CCell::vup=0.4;//0.3;// uptake strength 
const double CCell::taus=4.0;// diffusional delay (ms) 
const double CCell::gna=12.0;// sodium conductance (mS/micro F)  
const double CCell::taur=30.0;// spark lifetime (ms) 
const double CCell::taua=100.0;// NSR-JSR diffusional delay (ms) 
const double CCell::av=11.3; 
const double CCell::cstar=90.0; 
#endif 
 
#endif /* ___CELL_H */ 
 
UC.CPP 
#define ___REC_CURRENTS 
#define ___USE_VAR_FOR_CONST 
 
#include <iostream> 
using namespace std; 
#include "cell.h" 
#include "cell.cpp" 
 
int main(void) 
{ 
 CCell cell; 
 const double bcl=400.0; 
 
 int Tn=bcl*200/cell.getdt(), bcln=bcl/cell.getdt(), durn=1/cell.getdt(); 
 for (int tn=0;tn<Tn;tn++) 
 { 
  double t=tn*cell.getdt(); 
  if (tn%10==0 && t>=bcl*190)cout<<t-bcl*190<<"\t"<<cell.v<<"\t"<<cell.ci<<"\n"; 
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  if (tn%bcln < durn) 
   cell.Pace(50.0); 
  else 
   cell.Pace(); 
 } 
 return 0; 
} 
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